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The Genomic Evolution Of Breast Cancer Metastasis
Abstract
Part 1: Nearly all breast cancer deaths result from metastatic disease. Despite this, the genomic events
that drive metastatic recurrence are poorly understood. Whole-exome and shallow whole-genome
sequencing were employed to identify genes and pathways preferentially mutated or copy-number altered
in breast cancer metastases compared with the paired primary tumors in patients. Seven genes were
preferentially mutated in metastases: MYLK, PEAK1, SLC2A4RG, EVC2, XIRP2, PALB2, and ESR1. Four
regions were preferentially copy-number altered: loss of STK11 and CDKN2A/B, as well as gain of PTK6
and the membrane-bound progesterone receptor, PAQR8. PAQR8 gain was mutually exclusive with
mutations in the nuclear estrogen and progesterone receptors, suggesting a role in treatment resistance.
Several pathways were preferentially mutated or altered in metastases, including mTOR, CDK/RB, cAMP/
PKA, WNT, HKMT, and focal adhesion. Immunohistochemical analyses revealed that metastases
preferentially inactivate pRB, upregulate the mTORC1 and WNT signaling pathways, and exhibit nuclear
localization of activated PKA.
Part 2: It remains unclear whether alterations that drive breast cancer metastasis arise after
dissemination or were originally present and selected for within rare subclones in the primary tumor. To
this end, ~200 regions of interest were sequenced in both paired primary and metastatic tumors using
ultra-deep sequencing coupled with unique molecular identifiers (UDS-UMI) and mitigation of FFPEartifacts by uracil deglycosylase. Rare subclonal mutation burden within primary tumors was associated
with advanced stage at diagnosis and an increased frequency of alterations known to be associated with
primary tumorigenesis, and predicted the acquisition of specific metastasis-enriched genomic alterations
in metastases, including: gain of ERBB2 and PTK6; mutations in the focal adhesion, mTOR, WNT, and
cAMP signaling pathways; and nuclear localization of activated PKA. The majority (85%) of metastasisspecific mutations remained undetected in primary tumors, indicating that they were either present in less
than ~2-5% of cells within the primary tumor, occurred within unassayed regions, or arose after
metastatic dissemination. In a quarter of patients, metastasis-specific mutations were detected within
rare subclones in primary tumors, including a 2% cellular subclone that bore mutations in both the WNT
receptor, LRP5, and the metastasis-enriched gene, PEAK1. UDS-UMI enabled the detection of poly-clonal
dissemination two patients.
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ABSTRACT

GENOMIC EVOLUTION OF BREAST CANCER METASTASIS
Matt R. Paul
Lewis A. Chodosh
Part 1: Nearly all breast cancer deaths result from metastatic disease. Despite this, the genomic
events that drive metastatic recurrence are poorly understood. Whole-exome and shallow wholegenome sequencing were employed to identify genes and pathways preferentially mutated or
copy-number altered in breast cancer metastases compared with the paired primary tumors in
patients. Seven genes were preferentially mutated in metastases: MYLK, PEAK1, SLC2A4RG,
EVC2, XIRP2, PALB2, and ESR1. Four regions were preferentially copy-number altered: loss of
STK11 and CDKN2A/B, as well as gain of PTK6 and the membrane-bound progesterone
receptor, PAQR8. PAQR8 gain was mutually exclusive with mutations in the nuclear estrogen
and progesterone receptors, suggesting a role in treatment resistance. Several pathways were
preferentially mutated or altered in metastases, including mTOR, CDK/RB, cAMP/PKA, WNT,
HKMT, and focal adhesion. Immunohistochemical analyses revealed that metastases
preferentially inactivate pRB, upregulate the mTORC1 and WNT signaling pathways, and exhibit
nuclear localization of activated PKA.
Part 2: It remains unclear whether alterations that drive breast cancer metastasis arise after
dissemination or were originally present and selected for within rare subclones in the primary
tumor. To this end, ~200 regions of interest were sequenced in both paired primary and
metastatic tumors using ultra-deep sequencing coupled with unique molecular identifiers (UDSUMI) and mitigation of FFPE-artifacts by uracil deglycosylase. Rare subclonal mutation burden
within primary tumors was associated with advanced stage at diagnosis and an increased
frequency of alterations known to be associated with primary tumorigenesis, and predicted the
acquisition of specific metastasis-enriched genomic alterations in metastases, including: gain of
ERBB2 and PTK6; mutations in the focal adhesion, mTOR, WNT, and cAMP signaling pathways;
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and nuclear localization of activated PKA. The majority (85%) of metastasis-specific mutations
remained undetected in primary tumors, indicating that they were either present in less than ~25% of cells within the primary tumor, occurred within unassayed regions, or arose after metastatic
dissemination. In a quarter of patients, metastasis-specific mutations were detected within rare
subclones in primary tumors, including a 2% cellular subclone that bore mutations in both the
WNT receptor, LRP5, and the metastasis-enriched gene, PEAK1. UDS-UMI enabled the
detection of poly-clonal dissemination two patients.
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CHAPTER 1: GENOMIC LANDSCAPE OF METASTATIC BREAST CANCER IDENTIFIES
PREFERENTIALLY DYSREGULATED PATHWAYS AND TARGETS

1.1

Introduction
Breast cancer is the most prevalent cancer in the United States and the leading cause of

cancer mortality worldwide among women (1). Although 5-year survival rates approach 90%, up
to 30% of breast cancer patients ultimately die from their disease, typically due to disease
recurrence at distant sites following a variable period of clinical remission (2).
Historically, metastatic breast cancer was treated with the tacit assumption that key
biological features of primary tumors are preserved during metastatic outgrowth; however, more
recent findings challenge this belief. Indeed, the fact that primary breast cancer is frequently
curable, whereas metastatic breast cancer is not, suggests that important biological differences
exist between these 2 stages of tumor progression.
Because breast cancer mortality is principally due to metastatic disease, improving
outcomes for breast cancer patients will be facilitated by a detailed understanding of the biology
of metastatic evolution. Unfortunately, while the genomic landscape of primary breast cancer has
been extensively analyzed in over 2000 patients (3), analogous data for metastatic breast cancer
are relatively sparse.
Studies of recurrent breast cancer in preclinical models and patient cohorts (4-12) have
demonstrated that cancers undergo considerable molecular and cellular evolution during the
course of tumor recurrence. Consistent with this observation, hormone receptor (HR) and HER2
status are discordant between primary and metastatic tumors in 20% to 25% of patients (13).
Further, while most oncogenic driver mutations in primary tumors are retained within metastases
– as would be anticipated from their clonal relationship – metastatic tumors harbor additional
oncogenic mutations beyond those detected in their primary tumors of origin (8, 10, 12).
Recent studies using targeted sequencing panels in paired primary and metastatic
tumors, as well as high-throughput sequencing in unpaired metastases, have identified several
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genes that appear to be preferentially mutated in breast cancer metastases, including ESR1 (14),
ERBB2 (12), JAK2 (10), NF1 (12), PALB2 (6), STAT3 (10), and TSC1/2 (6). However, the
majority of metastatic breast cancers do not harbor mutations in these genes, suggesting that
others remain to be identified. Moreover, copy number alterations (CNAs) that preferentially occur
in metastases, as well as pathways that are preferentially mutated, have yet to be
comprehensively characterized. In this study, we sought to identify genes and pathways that are
preferentially mutated or copy-number altered within metastases compared with the primary
tumors from which they arose in order to elucidate potential drivers of metastasis and therapeutic
resistance.
1.2
1.2.1

Results
Genomic assays and tumor cohort
Whole-exome sequencing (WES) and shallow whole-genome sequencing (sWGS) were

performed to detect somatic coding mutations and genome-wide CNAs in paired primary and
metastatic tumors from 28 patients and unpaired metastases from 38 additional patients
(Appendix: Supplemental Table 1). Seventy-five percent of recurrent tumors were distant
metastases (liver [n = 36], brain [n = 3], lymph node [n = 3], lung [n = 2], soft tissue [n = 2], bone
[n = 1], contralateral breast [n = 1], ovary [n = 1], and skin [n = 1]), with the remaining tumors
consisting of locoregional recurrences (lymph node [n = 10], chest wall [n = 3], sternum [n = 2],
and ipsilateral breast [n = 1]). Primary tumors were predominantly invasive ductal carcinomas
(78.8%), with 6.1% exhibiting features of invasive lobular carcinoma and 10.6% exhibiting mixed
lobular and ductal features. All genomically assayed primary tumors were treatment naive. Four
metastatic tumors (6.1%) were synchronous, defined as having been biopsied within 3 months of
primary tumor resection, and arose in treatment-naive patients. The median time between
primary tumor resection and asynchronous metastatic tumor biopsy for the remaining samples
was 5.7 years (range: 9 months to 27 years). Biopsies of asynchronous metastatic tumors
occurred after patients had been exposed to at least 1 form of therapy: chemotherapy (74.2%),
radiation therapy (68.2%), antiestrogen therapy (72.7%), and/or anti-HER2 therapy (13.6%).
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Metastatic tumors in our cohort arose most commonly from primary tumors that
expressed estrogen receptor (ER) and/or progesterone receptor (PR), hereafter referred to as
HR+ (75.8%); 12.7% of metastatic tumors arose from HER2-amplified (HER2+) primary tumors, as
determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH).
Considered in combination, metastases in our cohort arose from primary tumors that were
HR+HER2– (69.8%), HR–HER2– (triple-negative breast cancer [TNBC], 17.5%), HR+HER2+
(6.3%), or HR–HER2+ (6.3%). Although HR/HER2 status was discordant between primary and
metastatic tumors in the same patient in 17.5% of cases, the distribution of HR/HER2 subtypes
was similar for primary and metastatic tumors in our cohort (Figure 1.1).
1.2.2

Genomic concordance and germline mutations
WES and sWGS performed on paired primary and metastatic tumors, coupled with multi-

region sequencing (MRS) of multiple blocks from the same tumor, revealed that somatic coding
mutations and whole-genome CN were each markedly less concordant for primary-metastatic
tumor pairs than for multiple regions of the same tumor (mean Jaccard index of shared mutations:
paired tumors = 0.29 ± 0.21, MRS = 0.78 ± 0.14, P = 5.4 × 10-7; mean R2 of genome-wide CN:
paired tumors = 0.55 ± 0.29, MRS = 0.86 ± 0.17, P = 3.8 × 10-4; Figure 1.2A). Notably,
concordance metrics for mutations and CN were highly correlated (P = 5.8 × 10-5, Figure 1.2B).
The extent of concordance observed between differentially preserved (i.e., FFPE vs. OCT) tumor
pairs did not differ significantly from the concordance observed between tumor pairs with the
same preservation type, indicating that the relatively low concordance between paired tumors
was independent of preservation type for both WES and sWGS.
As anticipated from their ancestral relationship, the majority of metastases were clonally
related to their primary tumors of origin, as evidenced by co-clustering of 27 out of 28 primarymetastatic tumor pairs according to recurrent somatic coding mutations (Figure 1.3). Metastases
exhibited a greater number of coding mutations (P = 6.9 × 10-5) and CNAs (P = 0.0093)
compared with the primary tumors from which they arose (Figure 1.2C). This was accompanied
by an increase in the number of large-scale state transitions (LSTs) in metastatic tumors (P = 3.1
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× 10-6), defined as the number of occurrences in which adjacent genomic segments of ≥10 Mbp
change CN state (15) and is a “genomic scar” indicative of homologous recombination deficiency
(HRD) (16) and BRCA1/2 loss-of-function (LOF) (17).
Consistent with prior reports (14), activating mutations in ESR1 (ERα) were detected in
metastatic tumors from 7 patients (10.6%), each of whom had been treated with antiestrogen
therapy before metastatic tumor biopsy. Mutations in PGR (PR), which are reportedly rare in
primary breast cancer and other cancers (18), were identified in 2 metastatic tumors, each of
which arose in patients treated with aromatase inhibitors. Four metastases (6.1%) harbored
activating mutations in ERBB2 (HER2), each of which was clonal and/or co-occurred with copy
number (CN) gain and/or loss of the WT allele. Metastases with ERBB2 mutations arose in both
HR–HER2+ and HR+HER2– primary tumors and in anti-HER2- as well as antiestrogen-treated
patients.
Ten patients (15%) exhibited germline variants of clinical significance (VCS): BRCA1 (n =
3; E23fs, S1253fs, A1729E), BRCA2 (n = 3; K1036*, W1692fs, K2013*), PALB2 (n = 2; R170fs,
Y1108fs), ATM1 (n = 1; V1602fs), and CHEK2 (n = 1; T410fs). All identified BRCA1, BRCA2,
and PALB2 germline variants were confirmed by targeted panel sequencing in a CLIA-certified
laboratory. The frequency of HRD-associated LSTs was increased in metastases that harbored at
least 1 germline VCS in BRCA1, BRCA2, or PALB2 (P = 0.024), which is consistent with their
roles as inherited breast cancer susceptibility genes that promote homologous recombination
repair (19).
All but 3 germline variants (BRCA2 K2013*, PALB2 R170fs, and PALB2 T1108fs) cooccurred with loss of heterozygosity (LOH) in their respective tumors. Both patients with germline
PALB2 mutations developed tumors harboring additional clonal somatic PALB2 mutations, likely
leading to loss of the WT allele and complete LOF. Furthermore, 3 metastases in patients
carrying WT germline alleles for BRCA1 and BRCA2 exhibited clonal somatic mutations
in BRCA1 or BRCA2 that co-occurred with LOH or mutation of the remaining allele. In total, 15%
(n = 10) of metastases were predicted to have complete LOF of BRCA1, BRCA2, or PALB2.
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1.2.3

Significantly mutated genes in metastases
Fifteen significantly mutated genes (SMGs) were identified in our metastatic tumor cohort

using MutSigCV2 (20). Seven SMGs are not significantly mutated in primary breast cancers in
The Cancer Genome Atlas (TCGA-BRCA), either within or across subtypes: ESR1, XIRP2,
PEAK1, PALB2, SLC2A4RG, MYLK, and EVC2. Five of these have not been reported as SMGs
by TCGA in any type of primary cancer: ESR1, MYLK, PEAK1, SLC2A4RG, and EVC2. An
additional 8 SMGs have previously been reported in TCGA-BRCA: PIK3CA, TP53, KMT2C/MLL3,
GATA3, RUNX1, CHD1, MAP2K4, and AKT1.
To determine whether the above 15 SMGs were preferentially mutated in treatmentrefractory metastases, we compared their mutational frequencies to those in primary breast
cancers from TCGA-BRCA (n = 1043). Mutations in TCGA-BRCA were first recalled using the
same variant-calling pipeline and stringency threshold criteria used in our study (see Methods).
Each of the 7 SMGs identified in our cohort that are not SMGs in primary breast cancer, as well
as RUNX1, exhibited significantly higher mutation frequencies in metastases compared with
TCGA-BRCA primary tumors using both the high-confidence thresholds employed in this study
and lower-confidence thresholds employed in the TCGA-BRCA study (3) (FDR ≤ 0.10; Figure
1.4A, Appendix: Supplemental Table 2). These differences in mutation frequencies persisted
when restricting the analysis to TCGA-BRCA samples with the highest gene coverage for each
SMG (Figure 1.5) and were not explained by differences in receptor subtype distributions
between the 2 data sets (Figure 1.1). Increased mutational frequencies were also observed
for TP53, KMT2C, and AKT1; however, these differences were not significant after accounting for
differences in coverage.
Interestingly, 3 SMGs involve the regulation of actin polymerization downstream of FAK
signaling: the myosin light-chain kinase MYLK (or MLCK) (21); the actin-binding protein XIRP2
(22); and the non-receptor tyrosine kinase, PEAK1 (23). Mutations in PEAK1 were either
nonsense (n = 2) or co-occurred with CN loss (n = 3), and recurrences generally exhibited
lower PEAK1 copy number (P = 0.035), suggesting that PEAK1 mutations in metastases are
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inactivating. SLC2A4RG is a transcriptional activator of the glucose transporter SLC2A4 (GLUT4)
(24). Mutations in SLC2A4RG in metastases co-occurred with CN gain, suggesting that they may
be activating. However, co-occurrence with CN gain may be incidental due to the proximity (~200
kbp) of SLC2A4RG to the putative CN driver, PTK6 (see below). Germline LOF mutations
in PALB2 result in inherited breast cancer susceptibility; however, PALB2 is not an SMG in
primary breast cancer. EVC2 encodes a transmembrane protein reported to be hypermethylated
in neoadjuvant treatment–resistant TNBC (25). LOF mutations in this gene result in the inherited
skeletal dwarfism disorder, Ellis-van Creveld (EvC) syndrome, and have been implicated in
defective hedgehog signaling (26) as well as elevated fibroblast growth factor signaling (27).
Mutations in MYLK and PEAK1 preferentially occurred in HER2+ metastases (P = 0.0017,
FDR = 0.04 and P = 0.0078, FDR = 0.13, respectively; Figure 1.4B) and in ERBB2-mutant
metastases (P = 0.016, FDR = 0.23 and P = 0.039, FDR = 0.36, respectively), with 1 HER2+
metastatic tumor exhibiting mutations in ERBB2, MYLK, and PEAK1. Mutations in these genes
are not correlated with HER2 status in primary breast cancers in TCGA-BRCA (P > 0.40),
suggesting that these associations may be specific to the metastatic, treatment-refractory setting.
Consistent with this, relapse-free survival (RFS) was reduced in TCGA-BRCA patients whose
primary tumors harbored mutations in MYLK (HR+HER2– tumors, P = 3.3 × 10–4, FDR < 0.01; all
tumors, P = 0.0038, FDR = 0.05; Figure 1.4C). No significant associations with RFS were found
for other metastasis-enriched SMGs, although statistical power was limited by the rarity of these
mutations in primary tumors.
1.2.4

Preferential focal CNAs in metastases
GISTIC2 (28) was used to identify focal genomic regions with significantly increased

frequencies of CNAs in either primary or metastatic tumors (FDR ≤ 0.10; Appendix: Supplemental
Table 3). Whereas all significantly altered regions (SARs) recurrently deleted (n = 20) in
metastases were reported by TCGA-BRCA within at least 1 breast cancer subtype, the majority of
recurrently amplified SARs (11 of 17) were unique to this metastatic tumor cohort, including
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1q32.1-q32.2, 3q29, 6p12.2, 6q25.1-q25.2, 7p22.1-21.3, 10q21.2, 14p13-q11.1, 15p11.1-q11,
17q21.1, 17q21.31, and 20p11.1-q11.21.
Two SARs were preferentially lost and/or exhibited decreased CN in metastases
compared with their primary tumor of origin: 19p13.3 (FDR = 0.03) and 9p21 (FDR = 0.13; Figure
1.6, A and B, and Appendix: Supplemental Table 3). Although 44 genes reside in 19p13.3,
STK11/LKB1 is located at its center and has previously been implicated as an oncogenic driver
for loss of this region (29). STK11 loss is predicted to down-regulate AMPK and up-regulate
mTOR signaling (30), is associated with poor prognosis in breast cancer, and has been
implicated in metastasis in a variety of cancers (31). Recurrent deletion of 9p21 occurs in a broad
spectrum of human cancers, including primary breast cancer (32), and has been ascribed to loss
of CDKN2A (encoding p14ARF and p16INK4A) and CDKN2B (encoding p15INK4B).
Two SARs were preferentially gained and/or exhibited increased CN in metastases
compared with their primary tumor of origin: 6p12.2 (FDR = 0.09) and 20p11.1-q11.21 (FDR =
0.07). The 78-kbp SAR within 6p12.2 contains only a single gene: the membrane-bound PR,
PAQR8 (mPRβ). mPRs have been reported to mediate rapid, nongenomic effects of
progesterone and to regulate cyclic adenosine monophosphate (cAMP) synthesis (33) and
apoptosis (34). Strikingly, in metastases arising in patients treated with antiestrogen therapy,
PAQR8 gain was mutually exclusive with mutations in either ESR1 or PGR (66.7% of
ESR1/PGR-WT metastases exhibited PAQR8 CN gain compared with 11.1% of ESR1/PGR
mutant metastases, P = 0.0062; ESR1 alone, P = 0.032; Figure 1.6D). Nevertheless, frequencies
of PAQR8 gain in metastases were similar in patients who had, or had not, been treated with
antiestrogen therapies (56% in each). These findings suggest that PAQR8 gain may contribute to
resistance to endocrine therapies as well as chemotherapy.
The preferential gain of 20p11.1-q11.21 observed in metastases was notable because
chr20q was amplified in its entirety in the majority of metastases in our cohort (57.6%, GISTIC2
FDR < 0.01). Because 20p11.1-q11.21 closely corresponds to the gene-poor pericentromeric
region of this chromosome, we considered that this SAR may simply represent a marker for
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increased chr20q CN in metastases compared with primary tumors (arm-level CN difference P =
0.0065, FDR = 0.09). Within this chromosome arm, 20q13.33 exhibited the largest CN difference
between paired primary and metastatic tumors (P = 9.1 × 10–4, FDR = 0.03 when included as a
GISTIC2-identified SAR; Figure 1.7). 20q13.33 contains the nonreceptor tyrosine
kinase PTK6 (BRK, breast tumor kinase), which is amplified and overexpressed in a variety of
human cancers (35). PTK6 has been reported to promote proliferation, survival and metastasis
(36), as well as resistance to targeted therapies (37), in part through its interaction with receptor
tyrosine kinases (RTKs) such as EGFR and ERBB2 (38).
Within the METABRIC data set (39), disease-specific survival (DSS) was significantly
shorter in patients whose primary tumors harbored loss of CDKN2A, loss of STK11, or gain
of PTK6 (P = 2.5 × 10–11, 0.0011, 0.0021, respectively; Figure 1.6C). This relationship also held
for ER+ tumors alone (P = 4.0 × 10–10, 6.9 × 10–4, 0.0063, respectively). PAQR8 gain was also
associated with decreased DSS, but only within the METABRIC CN cluster subtype, IntClust7
(P = 0.0020), which is a subgroup of luminal A tumors.
Aggregating P-values (Fisher’s method) across DSS associations within the METABRIC
study for loss of CDKN2A, loss of STK11, gain of PTK6, and gain of PAQR8 resulted in P = 1.6 ×
10-13. When testing the reverse direction for each gene (e.g., CDKN2A gain instead of loss), the
aggregate P-value was much greater (P = 0.078), demonstrating that the DSS associations of
these 4 SARs were specific to CN directions exhibited by metastases and, thus, not a result of
increased CN burden in metastases. This conclusion was further supported by comparing
aggregated P-values to 10,000 aggregated P-values generated by testing DSS associations of 4
randomly selected genes and CN directions. The true aggregate P-value was more significant
than 99% of permuted tests (Pperm = 0.009), whereas the aggregated P-value from testing reverse
directions was not significant (Pperm = 0.83). This provides further evidence that the DSS
associations of metastasis-enriched SARs do not simply result from an increased CN burden in
metastases. This was also true when the analysis was limited to ER+ tumors. When testing the
CN directions observed in metastases, the aggregate P-value (P = 2.6 × 10-12) was more
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significant than 97% of permuted tests (Pperm = 0.027). This was not the case when reverse
directions were tested (aggregated P = 0.33, Pperm = 0.94). Because these associations cannot be
attributed to increased CNA burden in metastases, these observations provide evidence for a role
for CDKN2A loss, STK11 loss, PTK6 gain, and PAQR8 gain in promoting metastasis and/or
treatment resistance.
1.2.5

Pathways preferentially mutated in metastases
Patient-oriented gene set enrichment analysis (40) identified 7 significantly mutated

KEGG-defined pathways (SMPs) in primary tumors, 43 SMPs in paired metastatic tumors, and 58
SMPs across all metastatic tumors (FDR ≤ 0.10). For 30 SMPs, significantly more patients
exhibited private mutations (i.e., mutations not shared between paired tumors, see Methods)
exclusively in the metastatic tumor and few, if any, patients had private mutations solely in the
primary tumor (FDR ≤ 0.10, Pperm ≤ 0.10; Appendix: Supplemental Table 4). Twelve of these
SMPs (mTOR Signaling, PI3K-AKT Signaling, Focal Adhesion, Progesterone-mediated Oocyte
Maturation, cAMP Signaling, Lysine Degradation, Regulation of Lipolysis in Adipocytes, Longevity
Regulating, VEGF Signaling, Prolactin Signaling, HIF-1 Signaling, and Carbohydrate Digestion
and Absorption) were also preferentially mutated in 211 metastatic tumors from Lefebvre et al. (6)
compared with 1,044 TCGA-BRCA primary tumors (Figure 1.8A, Appendix: Supplemental Table
5, and see Methods), which constitutes a significant overlap (P = 2.0 × 10–6).
Eighteen metastasis-enriched SMPs were identified in our primary/metastatic tumor data
sets, but not in the Lefebvre/TCGA-BRCA data sets (Figure 1.8B): Estrogen Signaling, Wnt
Signaling, Phospholipase D Signaling, Inflammatory Mediator Regulation of TRP Channels, Tolllike Receptor Signaling, Platelet Activation, Long-term Depression, Protein Digestion and
Absorption, Axon Guidance, Rap1 Signaling, Relaxin Signaling, Fluid Shear Stress and
Atherosclerosis, Fc Epsilon RI Signaling, Leukocyte Transendothelial Migration, Neurotrophin
Signaling, Sphingolipid Signaling, Autophagy-Animal, and TNF signaling.
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1.2.6

mTOR signaling is preferentially mutated in metastases
Summary of mutational pattern within the mTOR signaling pathway
Metastases preferentially harbored mutations in the mTOR signaling pathway both within

and beyond core RTK/PI3K/AKT pathway components (Figures 1.9 and 1.10). Of particular
interest were mutations in the amino acid–sensing subpathway (e.g., vATPase and GATOR1/2
complexes), WNT receptors and ligands (in which mutations were only present in metastases),
the MAPK pathway (in which all mutations were predicted to be activating), TSC1/2 core
regulators, and subunits of mTORC1/2. Though not previously reported in cancer, a mutation in
the mTORC2 subunit RICTOR, K1125E, is structurally similar to an acetylation mimic, K1125Q,
that constitutively activates mTORC2 independently of glucose levels (41). Overall, mutations
occurring in the mTOR pathway in metastases were consistent with mTOR activation in 26% of
cases, compared with only 9% of cases in which mutations suggested mTOR inactivation.
Beyond these mutations, the frequent and preferential loss of STK11 and gain of PTK6
observed in metastases would also be predicted to activate mTOR by inhibiting AMPK (30) or by
coactivating RTKs (38), respectively. Strikingly, STK11 loss was present in every metastasis that
arose from a primary tumor bearing a non-PIK3CA mutation in the mTOR Signaling gene set (P =
0.0047, FDR = 0.12; Figure 1.9C). Furthermore, STK11 loss co-occurred with PTK6 gain in
metastases (P = 0.038, FDR = 0.20, Figure 1.9D). This suggests that multiple alterations
predicted to activate mTOR may be coselected within treatment-refractory metastases.
Characterization of mutations within the mTOR signaling pathway
The mTOR Signaling pathway gene set was preferentially mutated in metastases
compared with primary tumors both in our paired tumor dataset (Pperm = 0.002) and in the
Lefebvre dataset compared with TCGA-BRCA (Pperm = 0.052). Mutations in the mTOR Signaling
pathway within metastatic tumors in our cohort occurred in several functionally distinct modules
(Figure 1.9), of which the most highly mutated was the core PI3K/AKT signaling pathway.
However, primary and metastatic tumors exhibited similar frequencies of PIK3CA mutations,
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which included common (H1047R/Q/L [n = 14], E545K [n = 6], E542K/Q [n = 4]) (3), as well as
rare, variants (E39K, C378W, E726K).
In contrast to mutations in PIK3CA, AKT1 mutations occurred solely in metastases and
included the activating mutations E17K (n = 3) and D323H (n = 1) (42, 43). Two novel AKT2
missense mutations, S398I and S1098R, were identified in a metastasis from 1 patient. An
additional patient harbored a 1 bp frameshift deletion in PTEN that co-occurred with focal deletion
in both primary and metastatic tumors, abrogating PTEN function. Mutations specific to the PI3KAKT Signaling gene set included components of JAK/STAT signaling (JAK1 [n = 3], JAK2 [n = 2],
JAK3, STAT5B), as well upstream growth factors (FGF10, FGF20, NGF), hormones (GH1, GH2),
and their respective receptors (FGFR4, GHR).
Metastases preferentially harbored mutations in mTOR modules other than PI3K/AKT,
including the MAPK, WNT, AMPK, and amino acid sensing pathways. Within the MAPK module
of the mTOR Signaling gene set, mutations occurred exclusively in metastases and co-occurred
with CN gain in 5 out of 6 tumors, with 1 metastasis harboring both the activating KRAS G12V
mutation and CN gain of MYC. Though not included in the mTOR Signaling gene set, 3
metastases (4.5%) exhibited mutations in NF1 that were likely deleterious (nonsense and/or cooccurred with deletion or copy neutral loss of heterozygosity). Mutations in the MAPK Signaling
gene set were also enriched in the Lefebvre dataset compared with TCGA-BRCA primary tumors
(Pperm = 0.029).
Upstream of MAPK and PI3K/AKT signaling, a large proportion of primary and metastatic
tumors harbored at least 1 mutation in an RTK (28.6% and 34.8%, respectively). Intriguingly,
PTK6, which is preferentially amplified in metastases, has been reported to interact with a
number of RTKs, thereby activating AKT1 (44-47). Although the mTOR Signaling gene set does
not include PTK6 nor most RTKs, their alteration would be anticipated to up-regulate mTOR
activity.
Metastatic tumors also exhibited significantly more mutations in the WNT signaling
module of the mTOR Signaling gene set (Figure 1.9B). Within the mTOR Signaling gene set,
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WNT pathway mutations were found exclusively in metastatic tumors and affected multiple WNT
ligands and receptors (LRPs and FZDs), including the LRP5 activating mutation, A65V (48).
TSC1/2 inhibition via upstream PI3K/AKT, MAPK, WNT, and AMPK signaling represents
a critical node in mTOR pathway activation. Four metastatic tumors, but no primary tumors,
harbored mutations in TSC1 (n = 3) and TSC2 (n = 1). TSC1/2 mutations have recently been
reported to be enriched in metastatic breast cancer compared with primary tumors (6), with
frequencies of 6% in both our cohort and the Lefebvre et al. dataset.
Unlike upstream pathways that affect mTORC1 activity by regulating TSC1/2, the amino
acid sensing module directly impacts mTORC1 activity. High concentrations of amino acids
induce binding of the Rag subfamily of Ras small GTPases (RagA/B/C/D) to Raptor, a component
of mTORC1 (49, 50). Rag binding, in turn, promotes localization of mTORC1 to the surface of
Rheb-containing amino acid-rich lysosomes, ultimately resulting in mTORC1 activation. Mutations
were identified in components of the v-ATPase complex (n = 6), which stimulates the ability of
Ragulator to promote mTORC1-Rag binding via Raptor. Additional mutations were identified in
genes that regulate mTORC1-Rag binding, including components of the GATOR1/2 complexes.
Overall, 22.7% of metastases, but only 7.1% of primary tumors, harbored mutations in the amino
acid sensing module (P = 0.061); moreover, 14 components of this module were mutated in
metastases, with only 2 being mutated in primary tumors (Figure 1.10).
Multiple novel mutations were identified in metastatic tumors within subunits common to
mTORC1 and mTORC2 (MTOR [n = 2], MLST8, DEPTOR), or specific to mTORC2 (RICTOR [n
= 2]). Intriguingly, while the RICTOR mutation, K1125E, has not been reported in human cancers,
acetylation of K1125 in response to elevated glucose and/or acetate levels activates mTORC2
independently of upstream PI3K/AKT signaling (41). Mutations were also found in several
downstream targets of mTORC1/2 involved in cytoskeletal organization, lipid biosynthesis,
autophagy, cell growth and proliferation. Particularly interesting amongst this group includes
mutations in 2 metastatic tumors in RHOA, G14E and G17V, the latter of which is frequently
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found in lymphomas where it promotes proliferation via activation of PI3K and MAPK signaling
(51).
Of the 36 mutations with known or putative effect, 24 (67%) mutations are predicted to
result in increased mTOR activity and 12 (33%) mutations are predicted to lead to decreased
mTOR activity, with mutations being consistent with activation in 17 (26%) metastases and
inactivation in 6 (9%) metastases (4 metastases had both activating and inactivating mutations).
1.2.7

mTOR is hyperactivated in metastases
IHC was performed to evaluate levels of phosphorylated ribosomal protein S6 (p-S6), a

functional read-out of mTOR activity (52), in 2 cohorts: 15 paired primary and metastatic tumors
that arose within the same patient, and 16 matched sets of primary and metastatic tumors that
arose in different patients. In the matched cohort, primary and metastatic tumors were matched
for tumor block age and preservation type, as well as the receptor subtype of the primary tumor
from which the metastasis arose (Figure 1.11).
Both mean p-S6 staining intensity (Figure 1.11B) and the proportion of tumor cells that
were p-S6+ (Figure 1.11C) were significantly higher in metastatic tumors than in their
corresponding primary tumors (median increase in intensity = 2.0-fold [IQR = 1.3–7.9], P = 9.8 ×
10–5; proportion of cells with p-S6 score = 3, P = 2.9 × 10–6; with score ≥ 2, P = 1.8 × 10–4; with
score ≥ 1, P = 0.0039). Differences in mTOR activity remained significant when paired and
matched tumor cohorts were analyzed separately (Figure 1.12, A and B). Importantly, p-S6
staining within the tumor stroma, nontumor stroma, and nontumor epithelium were not
significantly different between primary tumors and metastases, suggesting that observed
differences in p-S6 staining in tumor cells were not attributable to systematic technical differences
in processing of primary tumors and metastatic biopsies, such as time from excision to fixation
(Figure 1.12C).
Compared with their corresponding primary tumors, mTOR activity was elevated in both
liver and nonliver metastases (P = 0.013 and 0.0012, respectively; Figure 1.12D), and
irrespective of whether patients were treated with antiestrogen therapy or not (P = 0.001 and
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0.020, respectively; Figure 1.12E). Together, these genomic and biochemical findings
demonstrate that mTOR is hyperactivated in metastases compared with primary tumors.
1.2.8

Genomic alterations associated with mTOR activity
Genomic alterations in the mTOR pathway were evaluated for their association with p-S6

staining intensity in metastases (Figure 1.13). Surprisingly, neither PIK3CA mutation status
nor PTEN loss was associated with p-S6 intensity in metastases or primary tumors (Figure 1.14,
A and B). In contrast, mean p-S6 intensity was significantly higher in metastases that harbored 2
or more mutations in the mTOR Signaling pathway (P = 0.019), irrespective of PIK3CA mutation
status (Figure 1.14C). Three genomic alterations known to activate mTOR signaling were
significantly associated with increased p-S6 staining (Figure 1.11, D and E): ERBB2 mutation
(P = 0.0070), HER2+ status (P = 0.038), and loss of STK11 (P = 0.040). CNAs in 3 additional
genes not known to affect mTOR pathway activity were also associated with increased p-S6
staining: gain of PAQR8 (P = 0.018), gain of CCNE1 (P = 0.014), and loss of TP53 (P = 0.011).
For each of these alterations, p-S6 was elevated in both mutant and WT metastases compared
with genomically assayed paired primary tumors (Appendix: Supplemental Table 6). Notably, the
4 metastases with weakest p-S6 intensity all lacked the presence of any genomic alteration
associated with mTOR activity. Intriguingly, 3 of these metastases harbored mutations
in PIK3CA (n = 2) and/or loss of PTEN (n = 2). For 2 of these metastases whose paired primary
tumor was assayed by p-S6 staining, p-S6 intensity did not differ between the primary and
metastasis.
1.2.9

pRB is preferentially altered in metastases
In light of the frequent and preferential loss of CDKN2A in metastases, we estimated the

extent to which pathways impinging on pRB were dysregulated (Figure 1.15A). Three metastases
exhibited clonal mutations in CDKN2A (R80*, P81A, and D84N) within a mutational hotspot
known to abrogate the ability of p16INK4A to bind and inhibit CDK4 and CDK6 (53). Further, the
R80* mutation was estimated to be the only CDKN2A allele present, suggesting that p16INK4A was
entirely inactivated in this metastasis. Three additional metastases harbored mutations in RB1
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(n = 2) or RBL2 (RB2/p130), each of which was a frameshift mutation that was clonal and cooccurred with CN deletion. These mutational data suggest that pRB may be dysregulated in
metastases.
Consistent with the possibility of pRB inactivation in metastases, nearly twice the number
of high-level CNAs predicted to inactivate pRB were identified in metastatic tumors compared
with primary tumors (mean, primary = 1.1 ± 1.0, metastasis = 2.1 ± 1.7; P = 0.005), including
gains of CCNB1, CCND1, CCNE1, CCNH, CDK1, CDK2, CDK4, CDK6, CDK7, and MDM2, as
well as losses of CDKN2A, TP53, and RB1 (Figure 1.16). This imbalance is unlikely to result from
global increases in CNA frequencies in metastases, since the overall number of pRB-activating
CNAs observed in primary and metastatic tumors were similar (mean, primary = 0.8 ± 1.6,
metastasis = 0.6 ± 1.2; P = 0.55).
1.2.10 pRB is preferentially inactivated in metastases
To determine whether preferential inactivation of the CDK/RB pathway in metastases
occurred at the biochemical level, IHC was performed for phosphorylated pRB (phospho-RB), a
functional read-out of pRB inhibition, in a subset of tumors from the same cohort assayed for pS6 activity (Figure 1.15B). Compared with their corresponding primary tumors, metastases
exhibited significantly higher mean phospho-RB intensities within the tumor epithelium (median of
4.2-fold increase [IQR = 1.8–7.7], P = 5.1 × 10–4), as well as higher proportions of cells that were
phospho-RB+ (Figure 1.15, C and D). phospho-RB mean intensities were significantly higher in
metastases than primary tumors in both paired (n = 8) and matched (n = 15) tumor cohorts, liver
and non-liver metastases, and patients treated – or not treated – with antiestrogen therapy
(Figure 1.17). Together, genomic and biochemical analyses indicate that pRB is preferentially
inactivated in metastatic tumors.
Higher percentages of cells with saturated phospho-RB signal were observed in
metastases harboring a mutation in ERBB2 or loss of TP53 (score = 3; P = 0.032 and 0.067,
respectively). In addition, percentage positivity (score ≥ 1) and mean phospho-RB intensities
trended lower in metastases harboring fewer copies of RB1 (P = 0.088 and 0.13, respectively).
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Indeed, the metastasis with the lowest mean phospho-RB intensity was the only IHC-assayed
metastasis that harbored both a frameshift mutation in RB1 and RB1 deletion, underscoring the
inability of phospho-RB IHC to detect all forms of RB inactivation. Nevertheless, even after
normalizing for RB1 CN, no significant associations were found between genomic alterations and
levels of phospho-RB.
1.2.11 Concomitant alterations in mTOR and CDK/RB pathways
Mutations and CNAs in the mTOR and CDK/RB pathways significantly co-occurred in
metastases (Figure 1.18). CN values for CDKN2A in primary tumors were significantly associated
with CN values for STK11 in the metastases to which they gave rise (P = 1.9 × 10–4, FDR = 0.02).
The reverse was true as well, with CN values for STK11 in primary tumors being significantly
associated with CN values for CDKN2A in the metastases to which they gave rise (P = 0.0013,
FDR = 0.07). In an analogous manner, patients whose primary tumors harbored a nonPIK3CA mutation in the mTOR pathway gave rise to metastatic tumors with fewer copies
of CDKN2A (P = 0.0066, FDR = 0.15). More broadly, high-level CNAs predicted to activate
mTOR significantly co-occurred with those predicted to inactivate pRB (P = 2.7 × 10-4, Figure
1.18D), and mean p-S6 and phospho-RB staining intensities within metastases showed some
correlation (n = 23, P = 0.13). In aggregate, integrative genomic analysis indicates that mTOR
pathway activation and RB pathway inactivation co-occur in metastases, suggesting that
alterations in these pathways may cooperate during metastatic recurrence following therapy.
1.2.12 WNT signaling is preferentially mutated in metastases
The Wnt Signaling pathway gene set was identified as a metastasis-enriched SMP in our
cohort (Pperm = 0.029) and exhibited trending enrichment between the Lefebvre and TCGA-BRCA
datasets (Pperm = 0.22). Metastases harbored mutations in several genes within the WNT
Signaling gene set (Figure 1.19), including multiple WNT ligands (WNT1, WNT2B, WNT11) and
receptors (LRP5 [n = 2], LRP6 [n = 2], FZD1, FZD2, FZD3, FZD7, FZD10), as well as genes
involved in receptor-ligand interactions (WIF1 [n = 2], BAMBI, NOTUM, SERPINF1) and
regulation of Dvl (CSNK1E [n = 2], PRICKLE1, INVS, VANGL1), which affect downstream mTOR,
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MAPK, focal adhesion, and cell cycle pathways. Notably, 1 metastasis exhibited an activating
mutation in the WNT receptor, LRP5 A65V, which abrogates the ability of Dkk1 to inhibit LRP5
and resulting pathway activity (48).
Metastases also harbored mutations in genes that regulate b-catenin (CHD8 [n = 3],
APC2, AXIN1, FRAT1, CSNK2A1, CSNK2A3), cell cycle promoting transcription factors (SMAD4,
LEF1), ubiquitin-mediated proteolysis (CUL1, TBL1X, TBL1XR1), and calcium signaling (PLCB1
[n = 2], PLCB3 [n = 2], PLCB4, NFATC1, NFATC3, CAMK2D, PPP3CB, PRKCB). Similar
numbers of putatively activating and inactivating mutations occurred within canonical WNT (10
GOF and 9 LOF) and calcium (4 GOF and 4 LOF) signaling sub-pathways.
1.2.13 WNT is preferentially activated in metastases
IHC was performed to evaluate expression of β-catenin, a main effector of canonical
WNT signaling, in primary and metastatic tumors (n = 15, 7 paired and 8 matched sets, Figure
1.20, A–C). Activation of canonical WNT signaling may be accompanied by increased β-catenin
in the nucleus and decreased β-catenin at the cell membrane, where β-catenin is normally
sequestered by E-cadherin. Whereas most primary tumors (n = 13, 86%) exhibited some
membranous β-catenin staining, relatively few (n = 4, 27%) exhibited nuclear staining.
Metastases exhibited increased staining for both membranous (P = 0.0013, primary vs.
metastasis median intensity = 1.70 vs. 2.70) and nuclear β-catenin (P = 0.038, primary vs.
metastasis median intensity = 0.00 [max = 0.03] vs. 0.01 [max = 0.23]), with a larger proportion of
metastases exhibiting some nuclear β-catenin expression (P = 0.033, n = 10 [66.7%]). Further,
nuclear β-catenin expression was observed in metastases in each organ site tested: lymph node
(n = 2, max = 0.12), liver (n = 11, max = 0.15), and brain (n = 2, max = 0.23). Overall, β-catenin
levels in the membrane and nuclear compartments of metastases (but not primary tumors) were
negatively correlated (P = 0.046, R2 = 0.27). No significant associations were found between βcatenin expression and specific genomic alterations. Together, these data suggest that canonical
WNT signaling may be preferentially activated in metastases.
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1.2.14 cAMP/PKA signaling and related pathways are preferentially mutated in
metastases
Summary of mutational pattern in cAMP signaling and related pathways
Five metastasis-enriched pathways, cAMP Signaling, Progesterone-mediated Oocyte
Formation, Longevity Regulating, Carbohydrate Digestion and Absorption, and Regulation of
Lipolysis in Adipocytes share core PI3K/AKT/mTOR and cell cycle components with other
metastasis-enriched SMPs. Specific to these pathways, however, are genes that regulate the
synthesis and action of cAMP (Figure 1.21). cAMP serves as a second messenger in a broad
array of cellular processes, including apoptosis, metabolism, differentiation, and proliferation,
many of which are mediated through activation of the cAMP-dependent protein kinase, PKA (54).
Mutations in the cAMP Signaling pathway were significantly enriched in metastases and
occurred more frequently in metastases from patients who had been treated with either
chemotherapy or radiation therapy (P = 2.5 × 10–4). cAMP/PKA is the core effector of the
metastasis-enriched Progesterone-mediated Oocyte Formation pathway, which is thought to be
driven by nongenomic G protein–coupled mPRs, of which PAQR8 is a prominent member that
undergoes preferential CN gain in metastases (see above).
Characterization of mutations in cAMP signaling and related pathways
The cAMP Signaling pathway gene set was also identified as a metastasis-enriched SMP
in our cohort (Pperm = 0.045) and within the Lefebvre dataset compared with TCGA-BRCA (Pperm =
0.045). The second messenger, cyclic adenosine monophosphate (cAMP), mediates a broad
array of cellular processes, including apoptosis, metabolism, differentiation, and proliferation, and
exerts its effects primarily through activation of the cAMP-dependent kinase, PKA (54). Mutations
in this pathway (Figure 1.21) were identified in many genes whose products regulate cellular
cAMP levels, including adenylyl cyclases (ADCY10 [n = 2], ADCY4, ADCY5, ADYC6, ADYC7,
ADYC9); phosphodiesterases (PDE3A, PDE4D); a membrane transporter that regulates cAMP
efflux (ABCC4 [n = 2]); and G-coupled protein receptors that activate (ADRB1, DRD1, DRD5,
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TSHR, GLP1R, PTGER2) or inhibit (CHRM1 [n = 2], CHRM2, GHSR, GNAI3, HTR1B, HTR1F,
SSTR1, SSTR5) adenylyl cyclases.
Downstream of PKA, mutations were identified in several sub-pathways, including
PI3K/AKT, MAPK, Rac GEFs, and genes involved in the regulation of actin (described above).
Additional mutations were identified in genes involved in RAP1 signaling (RAPGEF4 [n = 3],
PLCE1, VAV1, VAV2), CREB binding (PPP1CB [n = 2], PPP1R12A [n = 2], PPP1CA, PPP1CC,
EP300 [n = 2], CREB3L3 [n = 2], CREB3L4, CREBBP), NFkB signaling (NFKB1, AMH), fatty acid
degradation (ACOX1), cell migration (ARAP3), and calcium signaling (NFATC1, CAMK2D), as
well as PKA-activated P-type primary ion transport ATPases (ATP1A1 [n = 2], ATP1A3 [n = 2],
ATP1A2, ATP1A4, ATP1B3, ATP1B4, ATP2A2, ATP2B1, ATP2B2), glutamate-regulated ion
AMP acid receptors (GRIA1, GRIA2, GRIA4), and glutamate-regulated ion N-methyl-D-aspartate
receptors (GRIN3A [n = 3], GRIN2A [n = 2], GRIN1 [n = 2], GRIN3B, GRIN2B). In total, 17
mutations were predicted to result in activation, and 12 mutations inactivation, of this pathway,
with mutations in aggregate being consistent with activation in 10 (15%), and inactivation in 6
(9%), metastases.
The Progesterone Mediated Ooctye Formation pathway gene set was also identified as a
metastasis-enriched SMP in our cohort (Pperm = 0.022) and when the Lefebvre dataset was
compared with TCGA-BRCA (Pperm = 0.028) and includes genes that regulate insulin and/or
progesterone-mediated inhibition of G2-arrest in Xenopus oocytes via activation of cyclin B. Like
several other metastasis-enriched pathways identified in this study, the Progesterone Mediated
Oocyte Formation pathway includes the core PI3K/AKT and MAPK pathways and affects genes
that regulate the cell cycle. Furthermore, like the cAMP signaling pathway, upstream activators
within the Progesterone Mediated Oocyte Formation pathway, such as insulin, are expected to
alter intracellular cAMP levels by regulating adenylyl cyclases. Though PAQR8 is not explicitly
included in this KEGG gene set, this pathway is described as being driven by G-protein coupled
non-genomic membrane-bound progestin receptors (mPRs) due to their ability to inhibit adenylyl
cyclase activity. Mutations unique to this metastasis-enriched pathway include regulators of
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APC/C (ANAPC7 [n = 2], ANAPC11), microtubule formation (KIF22 [n = 2], AURKA), CDK1/2
(PKMYT1 [n = 2], SPDYC), and the nuclear progesterone receptor, PGR (n = 2).
The Longevity Regulating pathway gene set was also identified as a metastasis-enriched
SMP in our cohort (Pperm = 0.076) and when the Lefebvre dataset was compared with TCGABRCA (Pperm = 0.0095) and includes genes that are involved in the ability of caloric restriction to
increase lifespan. Like other metastasis-enriched pathways, the Longevity Regulating Pathway
includes core PI3K, MAPK, mTOR, and cell-cycle pathways, as well as adenylyl cyclases and
subunits of CREB. Mutations within genes specific to this metastasis-enriched pathway include:
HKMTs (EHMT1, EHMT2), an adiponectin receptor, ADIPOR1; an AMPK kinase, CAMKK2 (n =
2); a subunit of PPAR-gamma, PPARGC1A; a pRB-regulator, RB1CC1, and regulators of insulin
signaling (IRS4 [n = 3], IRS2, KL, SESN3).
The Carbohydrate Digestion and Absorption pathway gene set was also identified as a
metastasis-enriched SMP in our cohort (Pperm = 0.055) and when the Lefebvre dataset was
compared with TCGA-BRCA (Pperm = 0.10). This pathway shares with the cAMP Signaling
pathway mutations in the core PI3K/AKT pathway and in PKA-activated P-type primary ion
transport ATPases. Unique to this pathway, however, are mutations in hexokinases (HKDC1 [n =
3], HK1 [n = 2]) and genes that regulate the initial digestion of sugars (MGAM, SI), as well as in a
G protein alpha subunit (GNAT3) and a G-protein coupled receptor (TAS1R3).
The Regulation of Lipolysis in Adipocytes pathway gene set was also identified as a metastasisenriched SMP in our cohort (Pperm = 0.0064) and when the Lefebvre dataset was compared with
TCGA-BRCA (Pperm = 0.035). Like other metastasis-enriched pathways, the Regulation of
Lipolysis in Adipocytes pathway includes core PI3K, MAPK, mTOR, and cell-cycle pathways, as
well as genes that regulate cAMP. Mutations in genes unique to this pathway include insulin
receptors (IRS4 [n = 3], IRS2), isoforms of PKG (PRKG1 [n = 2], PRKG1), which activate
perilipin, PLIN, and hormone-sensitive lipase, LIPE, in the presence of cGMP, as well as
downstream genes that regulate lipolysis (PNPLA2 and PNPLA2).
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1.2.15 Preferential nuclear localization of p-PKA in metastases
Phosphorylation of threonine 197 within the activation loop of the catalytic subunit of PKA
converts this enzyme to an active state. IHC was performed to evaluate expression of this
phosphorylated, activated form of PKA (p-PKA T197) within primary and metastatic tumors (n =
15; 7 paired and 8 matched sets; Figure 1.20, D–F). Cytoplasmic p-PKA was present in all tumors
assayed and did not differ between primary and metastatic tumors (median intensity, primary =
1.85 [IQR = 1.32–1.99], metastasis = 1.85 [IQR = 1.05–1.96]) (Figure 1.20E). In contrast, the
proportion of nuclei staining positive for p-PKA was substantially and significantly higher in
metastases compared with primary tumors (P = 8.1 × 10–4; median proportion, primary = 1% [IQR
= 0%–2%], metastasis = 11% [IQR = 6%–35%]) (Figure 1.20F). Nuclear p-PKA was observed in
more than 1% of tumor cells in only 4 primary tumors (27%), but was detected in more than 1% of
tumor cells in all metastases analyzed (n = 15, P = 2.5 × 10–5), and across all organ sites tested:
liver (n = 11), brain (n = 2), and lymph node (n = 2). No genomic alterations were identified that
were significantly associated with the presence of nuclear p-PKA. The preferential nuclear
localization of p-PKA (T197) in metastases suggests that cAMP/PKA signaling is preferentially
altered in metastases and may contribute to metastasis and/or the acquisition of treatment
resistance.
1.2.16 Preferential mutation of the focal adhesion pathway
Summary of mutational pattern in the focal adhesion pathway
Frequent mutations were identified in the Focal Adhesion pathway (Figure 1.22), the
majority of which occurred in collagens (26% of metastases harbored mutations in 14 members),
integrins (15% of metastases harbored mutations in 9 members), and laminins (11% of
metastases harbored mutations in 7 members). Mutations were also identified in a variety of
downstream genes regulating the actin cytoskeleton, including the metastasis-enriched SMGs,
MYLK, XIRP2, and PEAK1. Non-PIK3CA mutations in the Focal Adhesion pathway were
common and occurred at similar frequencies in patients who had, or had not, been treated with
antiestrogen therapy (75% and 78%, respectively).

21

FAK activation inhibits pRB via cyclin D1 (55) and activates mTORC1 (56) as a
consequence of shared signaling modules between the Focal Adhesion pathway and upstream
activators of mTORC1. Interestingly, 38% of metastases harbored unique mutations in both the
mTOR and Focal Adhesion pathways and Focal Adhesion–mutant primary tumors were more
likely to give rise to metastatic tumors with STK11 loss (P = 0.0013, FDR = 0.07) (Figure 1.22, B
and C). These observations suggest that concomitant dysregulation of the Focal Adhesion and
mTOR pathways may be selected for during metastatic outgrowth and/or contribute to treatment
resistance.
Characterization of mutations in the focal adhesion pathway
The Focal Adhesion pathway gene set was identified as a metastasis-enriched SMP both
in our tumor cohort (Pperm = 0.0013) and within the Lefebvre et al. dataset compared with TCGABRCA (Pperm = 0.078). Beyond shared modules with other metastasis-enriched pathways (e.g.,
RTKs, PI3K/AKT, WNT, and MAPK signaling), mutations in metastases were identified in several
components unique to the Focal Adhesion pathway (Figure 1.22). For example, within the “ECMReceptor Interaction” module, frequent mutations were identified in metastases in collagens (26%
of metastases harbored mutations in 14 members: COL1A1 [n = 2], COL4A4 [n = 2], COL4A5 [n
= 2], COL4A6 [n = 2], COL6A3 [n = 2], COL6A5 [n = 2], COL2A1, COL4A1, COL4A2, COL4A3,
COL6A2, COL9A1, COL9A2, COL9A3), integrin-a and b subunits (15% of metastases harbored
mutations in 9 members: ITGA9 [n = 2], ITGB4 [n = 2], ITGA1, ITGA11, ITGA4, ITGA7, ITGA8,
ITGB3, ITGB6), and laminins (11% of metastases harbored mutations in 7 members: LAMA3 [n =
4], LAMA1 [n = 2], LAMB1 [n = 2], LAMA4, LAMA5, LAMC1, LAMC3). Other gene families
mutated in this module included: platelet-derived growth factors and receptors (PDGFC, PDGFD,
PDGFRB), integrin-binding tenascins (TNXB [n = 2], TNC, TNN), and thrombospondins (THBS2
[n = 2], THBS3), which regulate collagen fibrillogenesis (55). Frequent mutations also occurred in
RELN (n = 6), which promotes cell adhesion to the ECM via activation of integrin-b1 (57), and
VWF (n = 4), which binds integrin-αvβ3 (58) and promotes platelet adhesion (59).
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Downstream of integrin signaling, mutations in metastases were identified in several
members of the FAK, SRC, RAS and RAC signaling cascades, including FAK and SRC genes
themselves, Rho GTPase activating proteins (ARHGAP5, ARHGAP35), and guanine nucleotide
exchange factor (GEF) activators of both Rac (VAV1, VAV2, DOCK1) and Ras (RASGRF1 [n =
3]). Within the “Regulation of Actin Cytoskeleton” module of the Focal Adhesion pathway gene
set, mutations in metastatic tumors were detected in the myosin light chain kinases, MYLK (n =
4), which was also identified as a metastasis-specific SMG, and MYLK3, as well as their
substrate, MYL10. Metastatic tumor mutations were also identified in actin-binding actinins
(ACTN1 [n = 2], ACTN4), regulatory subunits of protein phosphatase I (PPP1CB [n = 2],
PPP1R12A [n = 2], PPP1CA, PPP1CC), and regulators of actin assembly (TLN1, TLN2), crosslinking (FLNC [n = 3]), polymerization (PARVA [n = 2], RHOA [n = 2], ROCK1, DIAPH1, PXN),
and stabilization (PAK4). Finally, though not included in the Focal Adhesion gene set, we
identified 2 additional metastasis-specific SMGs whose functions impact on the actin
cytoskeleton: XIRP2 and PEAK1.
Of the 41 mutations with putative effect within collagens, laminins, thrombospondins,
integrin subunits, tenascins, and growth factors, as well FAK (PTK2) and SRC, 23 were GOF and
18 were LOF, with mutations being consistent with activation in 7 metastases and inactivation in
10 metastases (7 metastases had both GOF and LOF mutations).
1.2.17 Preferential mutation of histone lysine methyltransferases
Summary of mutations in HKMTs
The majority of mutations within the metastasis-enriched SMP, Lysine Degradation,
occurred in SET domain–containing histone lysine methyltransferases (HKMTs). Mutations
occurred most frequently within the KMT2 gene family, which methylate H3K4, a marker of
transcriptionally active chromatin. Metastases exhibited a significantly higher frequency of
mutations in KMT2C compared with TCGA-BRCA when confidence thresholds employed in the
TCGA-BRCA study were used (Figures 1.4 and 1.5). Mutations were also frequently identified in
the KMT1, KMT3, KMT5, and KMT8 gene families. Of note, mutations in HKMTs were enriched in
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metastases harboring somatic mutations in BRCA1, BRCA2, or PALB2 somatic mutations (P =
0.0049), but not in metastases harboring germline VCS in BRCA1, BRCA2, or PALB2 (P = 0.25).
The preferential mutation of HKMTs in metastases suggests the potential involvement of
epigenetic dysregulation in metastatic outgrowth and/or treatment resistance.
Characterization of mutations in HKMTs and the lysine degradation pathway
The Lysine Degradation pathway gene set was also identified as a metastasis-enriched
SMP in both our cohort (Pperm = 0.020) and when comparing the Lefebvre and TCGA-BRCA
datasets (Pperm = 0.041). Although several mutations were identified in metastases in genes
regulating acetyl-CoA production (ALDH7A1, ALDH9A1, COLGALT1, OGDH, PLOD2 and
TMLHE), the majority of mutations in this KEGG-defined pathway occurred in SET-domaincontaining histone lysine methyltransferases (HKMTs) from several different gene families. The
KMT2 family of lysine methyltransferases was the most frequently mutated and included KMT2C
(MLL3, n = 9), KMT2D (MLL4, n = 3), KMT2E (MLL5, n = 3), SETD1B (n = 3), SETD1A, ASH1L,
and KMT2A (MLL1), each of which methylate H3K4, a mark of transcriptionally active chromatin.
Mutations were also identified in KMT3 family members, NSD1 (n = 3) and SETD2 (n = 2), which
methylate H3K36 and H3K4, markers of actively transcribed genes, and in the KMT1 (EHMT1,
EHMT2, SETDB1, SUV39H1), KMT5 (KMT5B, KMT5C), and KMT8 (PRDM2) families, which
methylate H3K9, a marker of transcriptionally repressed chromatin. One mutation was found in
SETMAR, which is a fusion gene that contains a N-methyltransferase domain and a C-terminal
transposase domain. The majority of mutations in KMT2A/C/D within our cohort were deleterious.
Of the 20 mutations within HKMTs with putative effect, 13 (65%) are predicted to result in LOF
and 7 (35%) in GOF, with mutations being consistent with inactivation in 12 metastases (18%)
and activation in 6 metastases (9%).
1.2.18 HIF-1, VEGF, and prolactin signaling pathways are preferentially mutated in
metastases
The HIF-1 Signaling pathway gene set was also identified as a metastasis-enriched SMP
in our cohort (Pperm = 0.082) and when the Lefebvre dataset was compared with TCGA-BRCA
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(Pperm = 0.040). Like other metastasis-enriched pathways, the HIF-1 Signaling pathway includes
core PI3K, MAPK, and mTOR pathways, as well as JAK-STAT. Unique to this pathway, the
majority of mutations were identified in genes that are transcriptionally regulated by HIF-1. These
include: glucose metabolism regulators (hexokinases: HKDC1 [n = 3], HK1 [n = 2];
phosphofructokinases: PRKFB3 [n = 2], PFKL), iron binding transporters (TF, TFRC), an
endothelin (EDN1 [n = 2]), a nitrous oxide synthase (NOS2), a kinase that inhibits pyruvate
dehydrogenase (PDK1), and the glucose transporter SLC2A1 (also known as GLUT1).
The VEGF Signaling pathway gene set was also identified as a metastasis-enriched SMP
in our cohort (Pperm = 0.018) and when the Lefebvre dataset was compared with TCGA-BRCA
(Pperm = 0.10). Like other metastasis-enriched pathways, the VEGF Signaling pathway includes
core PI3K, MAPK, and mTOR pathways. Mutations in genes unique to this pathway include
genes that hydrolyze phospholipids (PLA2G4E [n = 2], JMJD7-PLA2G4B [n = 2]), the sphingosine
kinase, SPHK2, and calcium-dependent, calmodulin-stimulated protein phosphatase, PPP3CB.
The Prolactin Signaling pathway gene set was also identified as a metastasis-enriched
SMP in our cohort (Pperm = 0.013) and when the Lefebvre dataset was compared with TCGABRCA (Pperm = 0.0024). Like other metastasis-enriched pathways, the Prolactin Signaling pathway
includes core PI3K, MAPK, and mTOR pathways, as well as JAK/STAT components. Mutations
in genes unique to this pathway include nuclear estrogen receptors (ESR1 [n = 7], ESR2); the Gprotein coupled receptor, LHCGR (n = 2), which promotes ovarian steroidogenesis; the epithelialspecific Ets transcription factor, ELF5; a tumor necrosis factor, TNFSF11; and GCK (Hexokinase
4), which plays an important glucose regulatory role in liver and pancreatic islet beta cells.
1.2.19 Associations between metastatic sites and genomic alterations
Metastasis-enriched SMGs, SARs, and SMPs were evaluated to determine if their
presence was more likely to occur in metastases at specific sites. Compared with metastases at
other sites, liver metastases were enriched for HR+ tumors (P = 0.0035), exhibited lower STK11
CN (P = 0.022), and were less likely to harbor PTK6 gain (P = 0.041). Moreover, compared with
metastases at other sites, brain metastases exhibited higher PAQR8 CN (P = 0.016) and bone
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metastases were less likely to exhibit mutations in the metastasis-enriched Focal Adhesion (P =
0.012), cAMP Signaling (P = 0.029), and mTOR Signaling (P = 0.044) SMPs. However, these
associations did not retain significance following multiple-test correction.
1.3

Discussion
Breast cancer mortality is principally due to metastatic recurrence; however, little is

known about the biological differences between primary and metastatic tumors in patients. In this
study, WES and sWGS were performed on paired primary and metastatic tumors from 28
patients and 38 additional metastases to elucidate genomic events that occur during tumor
progression. A principal conclusion of this study is that metastatic tumors are biologically distinct
from the primary tumors from which they arise. Specifically, we found that metastases exhibit
markedly divergent mutational landscapes, frequently manifest a different ER/PR/HER2 status,
acquire additional oncogenic mutations, and exhibit increased genomic instability (Figure 1.23).
Most notably, nearly half of the SMGs identified in this study were more frequently mutated in
metastases than in primary tumors and have not been reported as SMGs in primary breast
cancers: MYLK, PEAK1, XIRP2, EVC2, SLC2A4RG, PALB2, and ESR1. Indeed, 5 of these
SMGs (MYLK, PEAK1, EVC2, SLC2A4RG, and ESR1) are not SMGs in any type of primary
human cancer in TCGA. In an analogous manner, of the 4 SARs identified as preferentially
altered in metastases (loss of STK11 and CDKN2A, gain of PAQR8 and PTK6), 2
(containing PAQR8 and PTK6) have not been reported in primary breast cancers in TCGA.
Together, our findings suggest that these 7 SMGs and 2 SARs, along with preferential alterations
in the mTOR, CDK/RB, cAMP/PKA, WNT, focal adhesion, and HKMT pathways, contribute to
aspects of metastasis that are not rate limiting for primary tumorigenesis and/or represent
pathways of therapeutic escape.
Integrated genomic analysis coupled with biochemical validation demonstrated robust
hyperactivation of mTOR signaling in metastases compared with primary tumors — a finding
bolstered by the observation that STK11 is preferentially lost, and PTK6 preferentially gained, in
metastases. mTOR pathway activation has been implicated as a mechanism of escape from
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therapies that target ER and HER2 in pre-clinical models (60) and in breast cancer patients (61).
Furthermore, treatment with the mTORC1 inhibitor everolimus improved progression-free survival
in patients with HR+HER2– metastatic breast cancer when administered along with an aromatase
inhibitor (62). Consistent with our findings, a reverse-phase protein microarray analysis identified
AKT/mTOR activation in liver metastases compared with unmatched primary breast cancers (63).
Unlike these prior findings, however, we observed increased mTOR activity in both liver and
nonliver metastases. Similarly, whereas mTOR has been reported to be preferentially activated in
breast cancer metastases in patients who received adjuvant endocrine therapy (61), we also
observed increased mTOR activity in metastases from patients who had not been exposed to
endocrine therapy. In aggregate, our data provide a genomic basis for the efficacy of mTOR
inhibition in patients with advanced breast cancer and further suggest that mTOR hyperactivation
in metastases occurs in contexts beyond those associated with antiestrogen therapy or
metastatic spread to the liver.
Mutational activation of PIK3CA is one of the most common oncogenic drivers of
HR+ primary breast cancer (64) and is generally presumed to activate mTORC1 via AKTmediated inactivation of TSC1/2. It is therefore notable that the increased frequency of mutations
that we observed in the mTOR pathway typically involved mTOR pathway components other than
PI3K and AKT, including those within the WNT, MAPK, and amino acid–sensing pathways. This
suggests that mutations within these pathways are nonredundant with PIK3CA and that activating
mutations in PIK3CA may not maximally activate mTORC1. Consistent with this, p-S6 staining
was not associated with PIK3CA mutation status, nor PTEN loss, but was instead associated with
ERBB2 mutations, HER2+ status, loss of STK11, and the number of non-PIK3CA mutations in the
mTOR pathway. Together, our results suggest that PIK3CA mutations alone do not result in
sufficient activation of mTORC1 to enable metastasis and/or confer therapeutic resistance in
breast cancer, and that multiple genomic alterations in this pathway may be required.
In this study, preferential inactivation of pRB in breast cancer metastases was first
suggested by integrative genomic analyses and then confirmed by IHC. Preferential inactivation
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of pRB was observed irrespective of metastatic site (liver or non-liver), or exposure to endocrine
therapy. In light of evidence that increased CDK4/6 activity in ER+ tumors is a demonstrated
mechanism of resistance to endocrine therapies (65), and that dual inhibition of CDK4/6 and ER
confers improved outcomes in patients with advanced breast cancer (66), our findings provide a
genomic basis for understanding the efficacy of CDK4/6 inhibitors in endocrine treatment–
refractory metastases.
Of note, the increased frequencies of CCNE1, CDK1, and CDK2 amplification observed
in metastases suggest that pRB inactivation in metastases may occur via activation of CDK1/2 as
well as CDK4/6. If true, this would imply that CDK4/6 inhibition alone may not achieve durable
responses in patients. Indeed, CCNE1 overexpression was associated with de novo resistance to
CDK4/6 inhibitors in the PALOMA-3 trial, which assessed dual palbociclib and fulvestrant
treatment in metastatic breast cancer (67), and with acquired resistance to CDK4/6 inhibitors in
breast cancer cell lines in vitro (68). Few studies to date have explored the utility of CDK1/2
inhibition in breast cancer, either alone or combined with CDK4/6 (69, 70).
Intriguingly, genomic alterations in the mTOR and CDK/RB pathways, as well as the
mTOR and focal adhesion pathways, preferentially co-occurred in metastases, whereby patients
whose primary tumors exhibited genomic alterations in one of these pathways were more likely to
give rise to metastases bearing genomic alterations in the other pathway. Furthermore, we found
that alterations that are expected to affect the CDK/RB pathway, including gain of CCNE1 and
loss of TP53, were significantly associated with mTOR activity in metastases, a finding that is
consistent with accumulating evidence for extensive crosstalk between mTOR signaling and cell
cycle regulators (71). Consequently, while studies of the ability of CDK4/6 inhibitors (PALLAS,
monarchE) or mTOR inhibitors (SWOG/NRG/Alliance S1207) to prevent metastatic recurrence in
early-stage breast cancer patients are underway, our findings that genomic alterations in these
pathways co-occur in patients suggest that combined pharmacological inhibition of mTOR and
CDKs may more effectively prevent, or treat, metastatic breast cancer than either agent alone.
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This prediction is supported by observations that dual inhibition of these targets results in more
pronounced antitumor effects in breast cancer xenografts and cell lines in vitro (71).
The WNT signaling pathway is a highly conserved regulator of embryonic development
(72) and has established roles in numerous aspects of cancer biology, including primary
tumorigenesis, metastasis and “stemness” (73, 74). Our study determined that patient
metastases preferentially mutate the WNT pathway and hyperactivate canonical WNT signaling,
as evidenced by an increase in both nuclear and membranous β-catenin. This hyperactivation is
consistent with correlative histopathological studies demonstrating that β-catenin expression in
primary breast cancers is associated with poor prognosis while being rarely localized to the
nucleus (75). Despite these prognostic studies, surprisingly few studies have assessed WNT
pathway activation in breast cancer metastases in patients. Whereas two studies failed to find
nuclear expression of b-catenin in brain (76) or liver (77) metastases, three other studies assayed
b-catenin in lymph node (78-80) and bone (79) metastases but did not address nuclear
localization. Our study demonstrates that nuclear localization of β-catenin preferentially occurs in
breast cancer metastases in patients and is evident in multiple organ sites (lymph node, liver, and
brain), indicating that metastases broadly and preferentially activate the canonical WNT signaling
pathway.
Interestingly, metastases exhibited increased expression of membranous β-catenin
compared with primary tumors, despite the anticorrelative relationship between membrane and
nuclear expression of β-catenin. An independent role for membranous β-catenin in promoting
cellular adhesion (81) is consistent with our finding that the Focal Adhesion signaling pathway is
preferentially mutated in metastases. In aggregate, our findings that metastases preferentially
mutate the WNT Signaling pathway, exhibit canonical WNT activation, and overexpress
membranous β-catenin, provide further evidence implicating WNT signaling in treatmentrefractory, metastatic breast cancer.
Like the mTOR, CDK/RB, and WNT pathways, the cAMP/PKA signaling pathway was
also preferentially mutated in metastases. Beyond our finding that cAMP/PKA pathway mutations
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are more common in patients exposed to either chemotherapy or radiation therapy, our study
demonstrates that localization of activated PKA to the nucleus preferentially occurs in treatmentresistant metastases in patients, and that this occurs at multiple organ sites. Consistent with this,
other studies have reported that phosphorylation of ER by PKA induces tamoxifen resistance in
vitro (82) and that translocation of pPKA to the nucleus mediates lung cancer metastasis in mice
(83). Nevertheless, despite its ubiquitous presence and broad cellular effects, cellular responses
to increased levels of cAMP are cell type and context specific (54, 84). It is therefore not
surprising that conflicting evidence exists regarding the role of PKA in tumorigenesis, metastasis,
and treatment resistance (85, 86). These apparent contradictions may be explained, at least in
part, by the differential abundance of PKA regulatory subunits (87), subcellular localization of
cAMP resulting from selective degradation by phosphodiesterases (PDEs) (88), and/or
subcellular localization of activated PKA through binding to compartment-specific A-kinase
anchoring proteins (89). Since both activators (e.g., forskolin) (90) and degraders (e.g., PDE4)
(91) of cAMP are being evaluated in the clinic, the complex effects of cAMP/PKA pathway
activation during cancer progression would benefit from further investigation.
Upstream of cAMP/PKA, we found preferential CN gain of the nongenomic PR, PAQR8,
in metastases. This alteration was mutually exclusive with mutations in the canonical nuclear
hormone receptors, ESR1 and PGR, and was associated with increased mTOR activity. Because
the role of progesterone in breast cancer remains largely enigmatic, an exciting avenue of
research will be to determine whether gain of PAQR8 results in increased mTOR or cAMP/PKA
pathway activity, is an escape pathway from ER blockade, or represents a distinct mechanism of
metastatic tumor dissemination or outgrowth distinct from canonical estrogen or progesterone
signaling.
Within the metastasis-enriched Focal Adhesion pathway, CN gain of PTK6 would be
anticipated to result in increased activity of its substrate, FAK (92). Three additional metastasisenriched SMGs are predicted to influence this same pathway. MYLK promotes adhesion
disassembly, cellular invasion, and formation of actin stress fibers (21, 93). PEAK1 promotes
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epithelial-to-mesenchymal transition via its association with the actin cytoskeleton and focal
adhesions (94), and XIRP2 protects against depolymerization of actin filaments (95). Our
observation that neither MYLK nor PEAK1 have been reported as SMGs in any other cancer type
in TCGA is consistent with a specific role for the focal adhesion pathway in metastasis and/or
treatment resistance that is distinct from its roles in primary tumorigenesis.
Though not an SMG in primary breast cancer, the metastasis-enriched SMG PALB2 is a
known breast cancer susceptibility gene (96). PALB2 plays a critical role in homologous
recombination through its interactions with BRCA1 and BRCA2 and, consistent with our findings
here, has recently been shown to be recurrently mutated in metastatic breast cancer (6).
Germline and/or somatic mutations in BRCA1, BRCA2, or PALB2 within metastases in our cohort
were relatively frequent, were predicted to result in complete LOF via LOH or mutation of both
alleles, and were associated with a concomitant increase in the number of LSTs, a marker of
HRD. Unexpectedly, mutations in BRCA1, BRCA2, and PALB2 significantly co-occurred with
mutations in HKMTs, which also were preferentially mutated in metastases, thereby suggesting a
potential link between HRD and the disruption of epigenetic regulators during tumor progression.
Together, our findings reveal that mutations affecting HRD-related genomic instability are
selected for during tumor progression, suggesting that metastases in a large proportion of breast
cancer patients may be rendered sensitive to platinum-based therapies and/or PARP inhibitors by
mutations in these genes.
Several recent reports have provided valuable insights into the genomic landscape of
metastatic breast cancer (4-12). However, the majority of these studies have been limited to
targeted panels of genes previously implicated in cancer, unpaired tumor cohorts, small sample
sizes, inclusion of treated primary tumors, and/or inference of CN based on non–genome-wide
sequencing. The present study evaluates the genomic evolution of breast cancer both in a large
cross section of metastases as well as in longitudinal paired primary-metastatic samples from the
same patient. By expanding assays beyond targeted cancer gene panels, preferentially mutated
and/or CN-altered genes could be identified in the metastatic setting beyond those frequently
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mutated in primary cancers. Moreover, preferentially mutated pathways were identified by
leveraging the knowledge that concordant pathway alterations may result from mutations in
multiple distinct pathway components, such that few individual genes are recurrently mutated. An
additional unique feature of the current study is that multiple pathways identified as recurrently
mutated at the genomic level were biochemically confirmed as altered in both paired and
unpaired metastatic tumors.
Despite these strengths, limitations of the current study include the challenges of
identifying subtype- and site-specific determinants of metastasis, which would require larger
sample sizes, particularly given the high frequency of HR+ liver metastases in our cohort. Our
study also did not address other known genomic drivers of cancer, such as noncoding variants,
genomic translocations, and transcriptional and epigenetic dysregulation.
In aggregate, our study highlights the divergent genomic evolution of metastatic cancers,
identifies potentially novel targets for combating metastatic progression and therapeutic escape,
provides a genomic basis for the efficacy of mTOR, CDK4/6, and PARP inhibitors, and suggests
WNT and nuclear PKA as drivers of breast cancer progression.
1.4
1.4.1

Methods
Methods Summary
WES and sWGS were performed to detect somatic coding mutations and genome-wide

CNAs in paired primary and metastatic tumors from 28 patients and in unpaired metastases from
38 additional patients. Tumors were available as formalin-fixed, paraffin-embedded (FFPE)
blocks and/or OCT-embedded frozen core biopsies in the form of intact tumor blocks, intact core
biopsies, or unstained 10-μm sections. ER, PR, and HER2 status were provided from clinical
annotation and were determined using standard practices by IHC and/or FISH.
WES variants were called using an ensemble approach, combining calls from 3 standard
pipelines. MutSigCV2 (20) was used to determine SMGs based on coding mutations and persample background mutation rates. SMG mutation frequencies were compared between
metastases in this cohort and variants from TCGA-BRCA that were recalled using the same
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variant-calling pipeline. Filtering threshold and per-sample coverage were carefully considered
when assessing increases in mutation frequencies.
sWGS CN values were estimated by adjusting read counts using QDNAseq (97) and
were corrected by locus and sample-specific parameters, tumor cellularity and ploidy. GISTIC2
(28) was used to determine SARs based on genome-wide CN. Patient-oriented pathway analysis
of somatic mutations was implemented based on approaches described in (40) and utilized
pathway gene sets defined by KEGG (98).
p-S6, phospho-RB, β-catenin, and p-PKA were assessed using IHC to evaluate activity of
the mTOR, CDK/RB, WNT, and cAMP/PKA pathways in 2 cohorts of primary and metastatic
tumors, the majority of which were genomically assayed. One cohort consisted of paired tumors
from the same patient; the other contained primary and metastatic tumors matched by tumor
block age, preservation type, and the receptor subtype of the primary tumor from which the
metastasis arose.
Three external datasets were used for in silico validation: re-called variants from primary
tumors from TCGA-BRCA (3), reported CNAs from primary tumors in METABRIC (39), and
reported variants from a cohort of metastatic tumors from Lefebvre et al. (6).
Clinical metadata, MutSigCV2 output, GISTIC2 output, and all described as well as
relevant mutations are provided as Supplemental Tables (Appendix). Raw WES and sWGS data
are publicly accessible in the NCBI BioProject, PRJNA610817.
Fisher’s exact test was used to compare mutant sample frequencies between primary
and metastatic tumor cohorts (e.g., ESR1 mutation). The Wilcoxon rank-sum test was used to
determine whether the number or extent of genomic events (e.g., CN values) within samples
were significantly different between the 2 cohorts (or subsets within a cohort). The Wilcoxon
signed-rank test was used to compare values between paired tumors. One-sided tests were used
throughout where appropriate unless otherwise noted. Univariate linear regression was used to
determine if 2 continuous features were correlated. Multiple testing correction and comparisons to
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permuted gene sets were used to evaluate significance, defined as FDR ≤ 0.10 and Pperm ≤ 0.10,
and are specified where applicable.
Each SAR was tested to determine whether mean CN values were significantly different
between paired primary and metastatic tumors (2-sided Wilcoxon’s signed-rank test) or whether
the distributions of low-level CNA frequencies (percentage loss, percentage normal, and
percentage gain) in primary tumors and the total metastatic tumor cohort were significantly
different (χ2 test). Metastasis-enriched SMPs were identified by comparing the proportion of
patients with private mutations solely in the primary tumor, solely in the metastatic tumor, or in
both tumors using a McNemar test. Kaplan-Meier curve survival analyses were used to assess
whether primary tumor mutations in SMGs were associated with decreased RFS in the TCGABRCA data set and whether primary tumor CNAs in implicated SARs were associated with
decreased DSS in the METABRIC data set. The extent to which these associations were specific
to implicated CN direction and were independent of CN burden was also assessed.
1.4.2

Breast cancer cohort
Patients with either newly suspected, untreated metastatic breast cancer or progressing

disease were eligible for the METAMORPH Study (“Metastatic Markers of the Recurrent
Phenotype”) if they had: 1) a history of histologically-confirmed primary breast cancer; 2) clinical
or imaging evidence suggestive of recurrent breast cancer in a local, regional, or distant location;
3) willingness to undergo and/or provide tissue from a recent biopsy of recurrent tumor for both
clinical and research testing; and 4) willingness to undergo blood specimen collection. Patients
were excluded if they were on anticoagulation that could not be interrupted for the purpose of
study procedures. Genomically assayed tumors were ascertained from the clinical practices of
the Rena Rowan Breast Center at the University of Pennsylvania, Philadelphia, Pennsylvania,
USA (IRB 1, Protocol 818874). Additional tumor specimens were provided for IHC analyses by
the TRACR (Breast Program Translational Cancer Resource) project (University of Pennsylvania
School of Medicine IRB 1, Protocol 811475).
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Approximately 50% of tumors were provided as 10µm sections and required macrodissection to remove non-tumor tissue, guided by top and bottom Hematoxylin and Eosin-stained
(H & E) sections. Tumor tissue from intact FFPE tumor blocks was isolated using a heating block
(58°C) and xylene was used for deparaffinization prior to DNA extraction. Intact OCT core
biopsies were thawed in a PBS bath at 4°C and the tissue washed 3 times in PBS at 4°C. DNA
was extracted from FFPE and OCT-preserved tumors using the Qiagen AllPrep DNA/RNA FFPE
Kit and Qiagen AllPrep DNA/RNA Micro Kit, respectively. Germline DNA was extracted from buffy
coat prepared from blood for each enrolled patient using the Qiagen Gentra Puregene Blood Kit.
1.4.3

Whole-exome sequencing
DNA was submitted for WES to the High-Throughput Sequencing Center at the

Children's Hospital of Philadelphia and the Beijing Genomics Institute (BGI). Sequencing was
performed on the Illumina HiSeq4000 using 100 bp or 150 bp paired-end reads using the
SureSelect v5 library preparation kit (Agilent). OCT and germline samples were sequenced at
100x and 50x target coverage, respectively. For FFPE samples, libraries were manually
generated and quality confirmed prior to sequencing to reach a target data size of 10GB (~50M
reads) after removal of low-quality reads.
WES reads were first trimmed for low-quality base-pairs (Trimmomatic v0.36) (99).
Paired reads and unpaired reads whose partners were removed during trimming were separately
aligned to hg38 (BWA v0.7.12) (100) and then merged (samtools v1.3.1) (101). Duplicated reads
were removed (PicardTools v2.6: http://broadinstitute.github.io/picard/) and the remaining reads
were realigned around indels (GATK v3.6) (102). After processing, median average coverage
across target regions was 108x [IQR = 85-123x] for tumors and 70x [IQR = 66-76x] for germline
samples.
Three variant callers were used to identify somatic mutations in tumors in reference to
matching germline samples: MuTect1 v1.1.4 (102), MuTect2 - GATK v3.6 (102), and VarScan
v2.3.4 (103). Default parameters were used for all steps of read processing and variant calling.
Variants called by at least 2 of the 3 callers were considered for further analysis. Variants that
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were reported in at least 1 normal sample by VarScan2 or were included in the MuTect2
generated “panel-of-normals” (PON), which includes variants and recurrent artifacts occurring in
at least 2 normal samples, were removed from further analysis. Variants were annotated using
snpEff v4.2 (104). VarScan was used to identify germline variants in normal samples and
VarfromPDB (105) was used to identify germline variants of clinical significance.
Three tiers of confidence were assigned to resulting variants – tier I: coverage ≥ 30
reads, alternative allele read coverage (AAC) ≥ 6, VAF ≥ 0.10; tier II: coverage ≥ 10 reads, VAF ≥
0.10; tier III: reported by at least 2 variant callers but did not meet tier I or II criteria. Since mean
concordance between sequencing replicates and differentially preserved tumor samples was
highest when limited to tier I mutations, analyses used tier I mutations unless otherwise stated.
Coding mutations are defined as those that were annotated as 1 of the following: missense,
splice-region, nonsense, start-loss, stop-loss, exon-loss, and exonic indel.
MutSigCV2 (20) was used to identify genes that were significantly mutated (SMGs)
based on tumor-specific mutation rates, mutation-specific nucleic-acid context, and gene-specific
length and nucleic-acid composition, using covariates (gene expression, replication timing, and
chromatin-state) provided by the Broad Institute, as well as a GC covariate provided by Ensembl
(106). In lieu of the proxy coverage data file provided for MutSigCV2 by the Broad Institute, perbase-pair/mutation-type coverage data was generated from aligned sequenced data specifically
from samples in this cohort. The significance of genes was only considered for those having
coding mutations in at least 4 samples in the metastatic tumor cohort.
1.4.4

Shallow whole-genome sequencing
For sWGS, DNA was first sheered to 350bp target size using a Covaris S220 sonicator

with the following parameters: 18W peak power, 20% duty factor, 50 cycles per burst, 65 second
duration, 20°C temperature, and water level at 2mm below cap of microTUBE-15. The Illumina
NeoPrep system was used to prepare libraries of single-end DNA reads, which were sequenced
on a NextSeq500 to a minimum of 6M 75 bp single-end reads per sample.
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Reads from sWGS were trimmed of low-quality base-pairs, aligned, then removed of
duplicates using the same WES processing tools described above. A median of 9.8M reads were
mapped, resulting in median coverage of 0.22x [IQR = 0.18-0.30x]. QDNAseq (97) was then used
to correct read counts across 15 kbp-wide genomic bins based on sequence mappability and GC
content, and to remove problematic genomic regions with blacklist status in the 1000 Genomes
Project (107). Hg19 was used as the reference genome for sWGS in order to take advantage of
existing reference annotations (97). CN values for resulting segments were calculated by
adjusting QDNAseq “signal” output by tumor-specific cellularity and ploidy identified by Sequenza
(108). DNA was unavailable for sWGS for 1 primary and 3 metastatic tumors that were assayed
by WES; CN calls from Sequenza were used as proxy for these samples. CNAs within
chromosome X were not included in analyses due to a lack of annotated “blacklist” regions, which
are used by QDNAseq for autosomal chromosomes.
Formulas for adjusted, relative, and normalized CN values are given below.
!"#$%&'" )* =

,%-./!0 × (304-"5 × 6'00$0!7-&5 + , × [: − 6'00$0!7-&5]) − , × (: − 6'00$0!7-&5)
6'00$0!7-&5

7'0!&->' )* =

!"#$%&'" )*
, /47@!0-A'" )* = 7'0!&->' )* × ,
304-"5

The median distance between K-means clusters of sample-specific CN segments was
used to identify cut-offs for low-level CNAs (CN loss [CN £ 1.74], CN gain [CN ³ 2.27]) and highlevel CNAs (deletion [CN £ 1.33], amplification [CN ³ 2.96]). Low-level cutoffs enabled the
identification of subclonal CNAs, whereas high-level cutoffs were used to limit analysis to clonal
and/or CNAs with multiple amplification or deletion events.
GISTIC2 (28) was used to identify focal regions and chromosome arms with significantly
increased frequencies of alterations (“SARs”, FDR £ 0.10) after providing all CN segments as
input. Focal regions are defined by GISTIC2 as those containing a high prevalence of CNAs
smaller than 98% of the length of the chromosome on which they reside. SARs containing subregions that were significantly altered in both primary and metastatic tumor cohorts were
combined into 1 distinct SAR spanning both identified SARs.

37

1.4.5

Multi-region sequencing and representative pairs
MRS was performed on tumors to evaluate variability resulting from intratumor

heterogeneity and technical sources. To accomplish this, WES and sWGS were performed on
DNA samples extracted from multiple tissue blocks from the same tumor. In the WES cohort, 3
regions were sequenced in 2 metastatic tumors, and 2 regions were sequenced in 1 primary and
5 metastatic tumors. In the sWGS cohort, 3 regions were sequenced in 1 metastatic tumor, and 2
regions were sequenced in 1 primary and 6 metastatic tumors. For 4 patients, 2 metastases from
different time-points were assayed. The majority of statistical analyses assessed 1 DNA sample
per tumor. Representative primary and metastatic tumor blocks were chosen to optimize the
similarity of preservation type and estimated tumor cellularity between matched primary and
metastatic tumors. Of these, 100% of primary tumors and 71% of metastatic tumors were
preserved in FFPE.
1.4.6

Genomic concordance
Genomic concordance based on somatic coding mutations was determined by percent-

overlap (Jaccard index) of tier I somatic coding-mutations in a pairwise fashion. Only loci that
were covered by at least 30 reads by WES in both tumors were considered. Genome-wide CN
concordance was determined by measuring the correlation (R2) of normalized CN across 15 kbpwide bins across the genome (n = 176,901 bins). CN values < 0.50 or > 8.00 were capped at
those values for this analysis.
1.4.7

External genomic datasets
To compare the frequency of genomic events between tumors in our cohort and tumors

from independent external cohorts, we processed raw sequencing data from 1,043 TCGA-BRCA
tumors (3) using the same alignment and variant calling pipeline used for our tumor cohort. Input
fastq files were extracted using biobambam (https://github.com/gt1/biobambam) from pre-aligned
BAM files downloaded from the NIH GDC data portal (https://gdc.cancer.gov/, date:10/20/2017).
Metadata for the full list of TCGA-BRCA samples included in this analysis are included in
Appendix: Supplemental Table 1. Since the number of called variants decreases with larger sized
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PONs, a representative PON was generated that was analogous to the one used for variant
calling in tumors in our study. First, 20 different PONs were generated using normal and artifact
calls from 68 randomly selected normal samples from TCGA-BRCA. The representative PON
was created using variant and artifacts calls present in at least 9 of 20 sub-selected PONs.
Variants in this representative PON were removed from TCGA-BRCA.
In addition, variant calls reported by TCGA from 775 primary tumors were downloaded
from the NIH GDC Legacy Archive (Level_2.5.3.0) and were re-annotated by snpEff with the
same version and annotation database configuration used for our data. When using established
variant thresholds employed by TCGA (3), the number of mutations per tumor sample was highly
correlated between the variant calling pipelines used in our analysis and by TCGA (R2 = 0.98, P £
2.2E-16). In an analogous manner, mutation calls from 211 metastatic tumors (6) were also reannotated using snpEff and are referred to as the Lefebvre et al. dataset throughout the
manuscript.
1.4.8

SMG frequency comparison
In order to determine whether metastases are enriched for mutations in SMGs compared

with primary tumors, mutational frequencies were compared with those from the TCGA-BRCA
primary tumor dataset (n = 1,042) using mutations called from our variant pipeline using stringent
filtering criteria (>30x coverage, VAF ³ 0.10, AAC ³ 6) and criteria established by TCGA (3) (>8x
coverage, VAF ³ 0.10, AAC ³ 2) using a 2-sided Fisher’s exact test. To evaluate whether
differences in SMG frequencies were dependent on the per-gene read coverage in TCGA-BRCA
samples, separate additional analyses were iteratively limited to the TCGA-BRCA samples with
highest coverage for a gene of interest (Figure 1.5).
1.4.9

Pathway analysis
Gene sets were downloaded from the KEGG pathway database (n = 320 gene sets) (98).

Seventy-three gene sets (the last set of gene sets listed in the database) were removed from
analysis because they did not refer to specific cellular pathways, but to genes involved with
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specific diseases (e.g., Type II Diabetes Mellitus, Prion Diseases). Twelve additional gene sets
were removed that contained fewer than 10 genes.
SMPs were identified within primary and metastatic tumors using an implementation of
the approaches described in POGSEA (40) which compares the observed number of tumors with
at least 1 mutation in a gene set of interest to the number of mutant tumors identified from 10,000
randomly chosen sets of genes with the same size as the gene set of interest. Genes were
sampled from those that are included in at least 1 gene set in KEGG (n = 6,509 genes). The
Benjamini-Hochberg method was then used to correct for multiple testing and identify the final set
of SMPs (FDR ≤ 0.10).
To identify pathways that were preferentially mutated in metastases compared with
primary tumors, mutations shared between paired tumors (tier I in 1 tumor and tier I-II in the
paired tumor) were removed and frequencies of private mutations within each pathway were
compared between tumors from the same patient using a McNemar test. Limiting to private
mutations allows the analysis to focus on metastatic tumor mutations that were either acquired
and selected following metastatic dissemination or were selected during dissemination from
small, undetectable populations of cells within the primary tumor. To address the concern that an
increased mutation frequency in a given pathway gene set may simply be a consequence of a
generally increased number of mutations in metastases, the test statistic generated from the
applied statistical method was compared with a distribution of test statistics generated from
10,000 equally-sized, randomly generated gene sets in order to compute a permutation P-value
(Pperm). Significant metastasis-enriched SMPs were defined as those with P ≤ 0.05, FDR ≤ 0.10,
and Pperm ≤ 0.10.
A similar approach was used to compare mutation calls generated by our pipeline for
1,042 TCGA-BRCA breast primary tumors and calls reported by Lefebvre et al. (6). In this
approach, TCGA-BRCA mutations were restricted to those satisfying filtering criteria used in
Lefebvre et al. (coverage ³ 10, VAF ³ 0.10, AAC ³ 5) (6). Since shared mutations cannot be
removed from external, unpaired datasets, PIK3CA and TP53 mutations were excluded since
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they were typically shared between primary and metastatic tumors in our cohort and because
they occur at high frequency (>30% in both primary tumors and metastases). Frequencies were
then compared using a 1-sided Fisher’s exact test and permutation, with significance being
defined as P ≤ 0.05, FDR ≤ 0.10, and Pperm ≤ 0.10.
1.4.10 Kaplan-Meier curve survival analysis
RFS curves were generated using Kaplan-Meier estimates and compared using a logrank test to determine if RFS in TCGA-BRCA patients was associated with primary tumor
mutations for each SMG. Time was defined by period between diagnosis and recurrence,
measured in months (“Disease_Free_months”), events were defined by whether the patient
recurred (“Disease_Free_Status”), and strata were defined by mutant status. Re-called TCGABRCA variants that passed filtering criteria established in (3) were included in the analysis.
For metastasis-enriched SARs, DSS curves were generated using Kaplan-Meier
estimates and compared using a log-rank test to determine whether each SAR was associated
with shortened DSS in METABRIC patients.
1.4.11 Immunohistochemistry
H & E stained slides were reviewed and representative sections chosen from each case
for immunohistochemical staining (IHC) for 4 markers (Table 1.1). A positive control and negative
rabbit or mouse isotype control (Leica Biosystems Inc, Buffalo Grove, IL, Cat. PA0777 and
PA0996) were included in each staining run. Prior to staining, heat-induced epitope retrieval was
performed for 20 min with Leica BondTM Epitope Retrieval Solution 1 (Leica, Cat. AR9961). IHC
was then performed on 5µm FFPE or OCT sections on a Leica Bond III auto-stainer for 15 min
according to the manufacturer’s instructions. Slides were arranged to eliminate covariates
between staining (row, column, and run batch effects) and tumor type. Detection was carried out
with the Leica Bond™ Polymer Refine Detection System (DS9800) with post-primary x 8 min and
HRP polymer x 8 min, and Diaminobenzidine (DAB) x 10 min. Prior to staining OCT sections,
slides were removed from -80°C storage and allowed to air dry for 30 min to remove moisture,
then rinsed in 1X Leica wash buffer (Cat. AR9590) twice for 2 min each, fixed in neutral buffered
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formalin for 10 min and rinsed in 1X Leica Wash Buffer. Without allowing slides to dry, slides
were loaded onto the Leica Bond III for retrieval and staining. Isotype controls, which were
performed for each stained section, did not show antibody staining in any case.
Antibody
Short Name
Phospho-S6 Ser235/236
p-S6
(clone D57.2.2E) rabbit mAb
(cat. #4858)
Phospho-Rb Ser807/811
phospho-RB
(clone D20B12) rabbit mAb
(cat. #8516)
β-catenin (clone 14) mouse
β-catenin
mAb (cat. #610154)
Anti-PKA alpha/beta/gamma
p-PKA
(catalytic subunit) phospho
T197 (clone EP2606Y) rabbit
mAb (cat. #ab75991)
Table 1.1: Antibodies used for IHC

Source
Cell Signaling, Danvers,
MA

Antigen Dilution
1:40

Cell Signaling, Danvers,
MA

1:50

BD Biosciences, San
Jose, CA
Abcam, Cambridge, MA

1:250
1:4000

p-S6 was stained in samples from 2 cohorts: paired primary and metastatic tumors that
arose within the same patient (15 patients), and matched primary and metastatic tumors that
arose in separate patients, wherein primary tumors were matched by tumor block age and
preservation type of the metastasis and for the receptor subtype of the primary tumor from which
the metastasis arose (16 matched sets, Figure 1.11), with the exception of 2 primary tumors for
which receptor status was unavailable. In total, p-S6 staining was performed on 31 metastatic
tumors from liver (n = 19), distant lymph nodes (n = 6), brain (n = 3), and soft tissue (n = 2), with
receptor subtypes: HR+/HER2- (n = 18), HR+/HER2+ (n = 4), HR-/HER2- (n = 5), HR-/HER2+ (n =
2), and unknown (n = 2). Phospho-RB was stained in a subset of samples from the paired (n = 8)
and matched (n = 15) tumor cohorts. In total, phospho-RB staining was performed on 23
metastatic tumors from liver (n = 16), distant lymph nodes (n = 5), and brain (n = 2), with receptor
subtypes: HR+/HER2- (n = 14), HR+/HER2+ (n = 2), HR-/HER2- (n = 3), HR-/HER2+ (n = 2), and
unknown (n = 2). b-catenin and p-PKA were stained in a subset of samples from the paired (n =
7) and matched (n = 8) tumor cohorts. In total, b-catenin and p-PKA staining were each
performed on 15 metastatic tumors from liver (n = 11), distant lymph nodes (n = 2), and brain (n =
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2), with receptor subtypes: HR+/HER2- (n = 10), HR+/HER2+ (n = 1), HR-/HER2- (n = 2), HR/HER2+ (n = 1) and unknown (n = 1).
Slides were separately scored for staining intensity in invasive tumor and adjacent nontumor compartments, each of which was further subdivided into epithelial and stromal subcompartments. Within each sub-compartment, the proportion of cells and/or nuclei that were
marker+ was estimated using the following scoring schema: 0 = no signal, 1 = low signal, 2 =
moderate signal, 3 = high signal. Mean staining intensities in each sub-compartment were
calculated using the percent of positive cells as weights. FFPE material was used in the majority
of cases, except for 7 metastases in the paired tumor cohort. No significant difference was
detected in mean p-S6 intensity between metastases preserved in OCT (mean = 0.85) and those
preserved in FFPE (mean = 1.3, P = 0.55). Scoring of phospho-RB within non-tumor
compartments could not be performed for the majority of non-liver metastatic tumor samples and
were excluded from analysis. Scoring for b-catenin and p-PKA were limited to the tumor
epithelium.
1.4.12 Associations between genomic and clinical attributes
Six distinct analyses were performed to determine the level of co-occurrence between
metastasis-specific SMGs, CNAs, and pathways across receptor subtypes, and to evaluate the
level of association of genomic features with IHC staining and metastatic tumor site. The first
analysis compared the co-occurrence of mutations between all SMGs and ERBB2 with receptor
subtype in the entire metastatic tumor cohort. The second analysis tested the association within
the entire metastatic tumor cohort between metastasis-enriched CNAs (STK11, CDKN2A, PTK6,
PAQR8) both via low-level CN dichotomized events and continuous CN values, mutations in
metastasis-enriched SMPs, and receptor subtypes. The third analysis was the same as the
second but was limited to paired primary and metastatic tumors. The fourth analysis investigated
enrichment of metastatic tumor site with receptor subtype, as well as mutations and alterations
within SMGs, SMPs, and SARs. The fifth analysis evaluated the association of p-S6 staining
intensity and positivity with genomic features identified in this study. Only features that were

43

present in at least 3 affected metastases were included: mutations in SMGs (PIK3CA, TP53,
KMT2C, RUNX1, MYLK, PEAK1, EVC2) and therapeutic targets (ESR1, ERBB2), CNAs (loss of
TP53, PTEN, RB1, CDKN2A, and STK11; gain of CCNE1, CDK2, CDK4, CDK6, and PTK6), as
well as whether metastases harbored ³ 1 or ³ 2 non-PIK3CA mutations in the mTOR Signaling
pathway. The sixth analysis, which sought to identify covariates of phospho-RB signaling, used
the same features as the fifth analysis, but also included the number of pRB-inactivating CNAs
and mutations as features. In the first 4 analyses, Fisher’s exact tests and Wilcoxon rank-sum
tests were 2-sided. The fifth and sixth analyses used Wilcoxon rank-sum 1-sided tests. For each
of these analyses, multiple test correction was implemented separately, with FDR values
provided in the text.
Two additional analyses tested specific hypotheses and were not amenable to multiple
test correction. The first tested an association of PAQR8 gain with ESR1/PGR mutations in
endocrine treated tumors. The second tested an association of high-level CNAs in the mTOR
pathway (deletion of STK11 and amplification of PTK6) with high-level CNAs in the CDK/RB
pathway that are (1) predicted to inactivate pRB and (2) exhibited some level of enrichment in the
total metastatic tumor cohort compared with the primary tumor cohort (P < 0.20, deletion of
CDKN2A and amplifications of CCNE1, CDK2, CDK4, CDK6). Both tests used 2-sided Fisher’s
exact tests.
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Figure 1.1: Global distribution of HR/HER2 receptor subtype is not significantly different
between cohorts in the present study and TCGA-BRCA. Bar-plots show the % of HR/HER2
subtypes in paired primary tumors (dark blue, n = 63), metastatic tumors (red, n = 66), and
TCGA-BRCA primary tumors (light blue, n = 906) with complete receptor subtype information. c2
P-values indicate no significance difference in receptor subtype distributions between the 3
cohorts.
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Figure 1.2: Paired primary-metastatic tumors are genomically distinct. (A) Concordance for
coding mutations (Jaccard index) and genome-wide copy number (R2) between primarymetastasis tumor pairs (orange, n = 28), multiple regions assayed from different tissue blocks
from the same tumor (purple, n = 14), and sequencing replicates (green, n = 12). Concordance
between primary-metastasis tumor pairs is substantially lower than concordance values between
multiple regions within the same tumor (1-sided Wilcoxon’s rank-sum test). Dashed vertical lines
indicate mean concordance between unrelated tumors. (B) Concordance determined for coding
mutations and genome-wide CNs are significantly correlated, R2 = 0.47. Columns represent
primary-metastasis tumor pairs. (C) Metastases (M) exhibit increased numbers of somatic coding
mutations, CNAs, and LSTs compared with the primary tumors (P) from which they arose (1sided Wilcoxon’s signed-rank test). Colored lines indicate patients for whom metastatic tumors
exhibited an increased (red) or decreased (blue) number of alterations compared with primary
tumors from which they arose.
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Figure 1.3: Primary-metastasis tumor pairs cluster by recurrent mutations and genomewide CN. Dendrograms showing hierarchical clustering of all tumors in the paired tumor cohort
using recurrent mutations (left) or genome-wide CN similarity across the top 50% most variable
genomic bins (right). Tumors that co-cluster with their paired tumor are indicated by blue boxes.
27 out of 28 primary-metastatic tumor pairs cluster by shared mutations. Despite tumors from
patient 16-13 appearing to co-cluster, they do not share mutations with each other. A majority of
tumor pairs co-clustered by genome-wide CN similarity.
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Figure 1.4: Genes preferentially mutated in metastases. (A) Mutation frequencies for SMGs
identified by MutSigCV2 within metastatic tumors in our cohort (red, n = 66) and primary tumors
in TCGA-BRCA (blue, n = 1044). Seven SMGs, indicated in bold, have not been reported in
TCGA-BRCA primary tumors across nor within subtypes. Eleven SMGs exhibited significantly
higher mutation frequencies in metastases within our cohort compared with TCGA-BRCA primary
tumors (2-sided Fisher’s exact test; *FDR ≤ 0.10; **FDR < 0.001). Red and orange asterisks
respectively denote 3 SMGs that either lose or gain significance when less stringent filtering
criteria employed in Ciriello et al. (3) are used. (B) Co-occurrence of MYLK and PEAK1 mutations
with ERBB2 mutations and HER2+ status in metastases (2-sided Fisher’s exact test, *P < 0.05;
**P < 0.01; FDRs = 0.07–0.36). Each column represents a metastatic tumor. (C) Kaplan-Meier
survival analysis showing that TCGA-BRCA patients whose primary tumor had a mutation
in MYLK exhibited shorter RFS.
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Figure 1.5: Identification of metastasis-specific SMGs is largely independent of sequencing
coverage in TCGA-BRCA. The degree to which SMG mutation frequencies are significantly
different between metastases in the present cohort and TCGA-BRCA primary tumors, as shown
across iteratively smaller subsets of TCGA-BRCA primary tumors with the highest coverage for
each gene in question. Red horizontal lines indicate mutation frequencies for metastases in the
present cohort. Black dotted lines indicate mutation frequencies across increasingly larger
subsets of TCGA-BRCA primary tumors using high-confidence criteria. TCGA samples are
ordered by decreasing sequencing coverage, with sample sets left of the grey solid and dashed
lines having at least half of the gene coding region covered by at least 30 and 10 reads,
respectively. Asterisks denote level of significance (2-sided Fisher’s exact test, ** FDR<0.01; *
FDR<0.10).
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Figure 1.6: Copy number alterations enriched in metastases. (A) Frequencies of CN gain
(red) and CN loss (blue) within primary (P, n = 28) and metastatic (M, n = 66) tumors for 4 SARs
preferentially altered in metastases. Low-level CNAs (gain and loss) and high-level CNAs
(amplification and deletion) are shown as lighter- and darker-colored bars, respectively.
χ2 P values indicate the degree to which the distributions of low-level CNA frequencies are
different between primary and metastatic tumors. Putative driver genes for each SAR are
indicated. (B) Normalized CN values for paired primary and metastatic tumors (2-sided
Wilcoxon’s signed-rank test). (C) Kaplan-Meier survival analysis within the METABRIC data set
(n = 1483) showing association of 3 of 4 identified metastasis-enriched SARs with shorter DSS.
(D) Gain of PAQR8 in metastases is mutually exclusive with mutations in ESR1 or PGR in
patients treated with antiestrogen therapy (2-sided Fisher’s exact test). Each column represents a
metastatic tumor.
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Figure 1.7: Inference of PTK6 as a driver of 20q amplification. (Top) Degree to which the
difference in normalized CN between paired primary and metastatic tumors is significantly
different across chr20q (2-sided Wilcoxon signed-rank test). (Bottom) Frequencies of CN gain in
all assayed primary and metastatic tumors. The metastasis-enriched SAR, 20p11.1-q11.21, is
indicated by grey lines and tightly corresponds to the centromere of chr20 (red box above).
Dashed green lines indicate the region with peak significance difference between paired primary
tumors and metastases, which contains PTK6 and ZBTB46. Dashed orange line indicates a
region containing ZNF217 where the frequencies of CN gain in both primary and metastatic
tumors were the highest and most similar to each other.
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Figure 1.8: Pathways preferentially mutated in metastases. Thirty pathways that were
preferentially mutated in metastases compared with paired primary tumors. (A) SMPs identified in
the current study as being enriched in metastases from this cohort as well as in metastases from
Lefebvre et al. (6) compared with TCGA-BRCA primary tumors. (B) SMPs enriched in metastases
in this cohort, but not enriched in Lefebvre et al. compared with TCGA-BRCA. Significance in the
local cohort was determined by comparing the fraction of primary-metastasis tumor pairs in which
only the primary tumor has a private mutation (blue), only the metastatic tumor has a private
mutation (red), or both primary and metastatic tumors have at least 1 private mutation (purple)
(McNemar’s test; FDR < 0.10). Permutation analysis was used to control for the global increase
in coding mutations within metastases (*Pperm < 0.10, **Pperm < 0.05, ***Pperm < 0.01).
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Figure 1.9: Mutations in the mTOR pathway in metastases. (A) Mutations in the mTOR
pathway in metastatic tumors occur within multiple signaling modules. Gene names in red
indicate genes mutated in ≥1 metastases (1.5%), with frequencies provided for genes mutated
>1. Frequencies of PTK6 CN gain and STK11 CN loss are indicated. (B) Mutation frequencies of
each module in primary (blue) and metastatic (red) tumors. Metastases exhibited a significantly
higher mutation frequency of the WNT signaling module compared with primary tumors (P =
0.010). (C) Co-occurrence analysis showing that primary tumors (P) with non-PIK3CA mutations
in the mTOR Signaling pathway gene set were more likely to give rise to metastases (M) with loss
of STK11. (D) Co-occurrence analysis showing that PTK6 gain and STK11 loss significantly cooccur in the total metastatic tumor cohort.
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Figure 1.10: Fewer non-PIK3CA mTOR pathway mutations in primary tumors.
(A) Non-PIK3CA mutations in the mTOR pathway occur infrequently in primary tumors compared
with metastases. Gene names in red indicate genes mutated at least once in primary tumors
(4%), with frequencies provided for genes mutated more than once. Frequencies of CN gain of
PTK6 and CN loss of STK11 are also indicated. (B) Frequencies of tumors with a mutation in
each of the mTOR signaling modules, as also given in Figure 5. The majority of mTOR pathway
mutations in primary tumors occur in RTKs and PI3K/AKT signaling components.
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Figure 1.11: mTOR is preferentially activated in metastases. (A) Representative p-S6 IHC
images for primary-metastasis tumor pairs from the same patient (n = 15), and primary and
metastatic tumors matched for tumor block age, preservation type, and receptor subtype of the
primary tumor from which the metastasis arose (n = 16). p-S6 IHC intensity scoring scale (no pS6 signal = 0, saturated signal = 3), with isotype control. (B) Mean p-S6 intensity and (C)
proportion of cells that are p-S6+ in paired and matched primary (P) and metastatic (M) tumors (1sided Wilcoxon’s signed-rank test). (D) Mean p-S6 intensity and (E) proportion of cells that were
p-S6+ (score = 3) in metastases WT or mutant for genomic features that either exhibited a
significant (1-sided Wilcoxon’s signed-ranked test, P < 0.05, white) or nonsignificant (gray)
association with p-S6 intensity. Gene names refer to genes that are mutated, unless in reference
to low-level CN gain or loss. “mTOR (≥x)” indicates the presence of at least x number of nonPIK3CA mutations in the mTOR Signaling pathway.
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Figure 1.12: mTOR pathway hyperactivation in sub-cohorts of metastases. Differences in pS6 staining intensity in primary and metastatic tumors as a function of tumor compartment,
scoring metrics, and tumor or patient characteristics. Line colors indicate the change in p-S6 from
primary tumors to their paired or matched metastases (red = increase, blue = decrease). P-values
indicate the degree to which changes in p-S6 measures are concordant (1-sided Wilcoxon
signed-rank test). (A) Mean p-S6 IHC staining intensity and (B) proportion of p-S6+ cells in
primary-metastasis tumor pairs from individual patients (top), and primary and metastatic tumors
matched by receptor status, tumor block age and fixation method (bottom). (C-E) Differences in
mean p-S6 intensity within (C) epithelial and stromal compartments in tumor and non-tumor
tissue, (D) liver and non-liver metastases, and (E) metastases in patients with, or without,
exposure to endocrine therapy.
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Figure 1.13: Identification of p-S6 covariates. Evaluation of genomic features as biomarkers of
mTOR activity (p-S6 staining intensity) in metastases (1-sided Wilcoxon rank-sum tests). Gene
names refer to mutations, unless in reference to low-level CN gain or loss. “mTOR (≥X)” indicate
the presence of at least X number of non-PIK3CA mutations in the mTOR Signaling pathway
gene set. HR+, HER2+, and TNBC refer to receptor subtypes of assayed metastases. Manhattan
plot indicating levels of significance for associated features with either mean p-S6 intensity or
percent cells with p-S6 scores ≥1, ≥ 2, or = 3. The dash line indicates a P-value cutoff of 0.05.
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Figure 1.14: Loss of PTEN and mutations in PIK3CA are not associated with mTOR activity.
(A, B) Mean p-S6 staining intensity in primary (left) and metastatic (right) tumors for those mutant
(“mt”, red) or WT (“wt”, blue) for (A) loss of PTEN and (B) mutation in PIK3CA. P-values indicate
that mean p-S6 activity was not significantly different in tumors mutant for these genes (2-sided
Wilcoxon rank-sum test). (C) Mean p-S6 staining in metastases as a function of the number of
mTOR pathway mutations in each tumor. Mean p-S6 staining intensity in metastases was
significantly correlated with the total number of mutations in the mTOR Signaling pathway gene
set when including PIK3CA (left) or excluding PIK3CA (right) mutations from the analysis
(univariate linear regression).
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Figure 1.15: RB is preferentially inactivated in metastases. (A) Pathway schematic of genes
downstream of p16INK4A/p14ARF and/or upstream of pRB. Solid and dashed lines indicate direct
and indirect relationships between gene products. The frequencies of high-level CNAs (upper)
and mutations (lower, where provided) in each gene are shown for primary tumors (left) and
metastases (right) beneath each gene. (B) Representative phospho-RB IHC images for paired
(n = 8) and matched primary and metastatic tumors (n = 15). (C) Mean phospho-RB staining
intensity and (D) proportion of cells that are phospho-RB+ in paired and matched primary and
metastatic tumors (1-sided Wilcoxon’s signed-rank test).
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Figure 1.16: Frequencies of low- and high-level CNAs in the CDK/RB pathway.
Frequencies of CN gain (red) and CN loss (blue) within primary and metastatic tumors are shown
for genes downstream of p16INK4A/p14ARF and/or upstream of pRB. Low-level CNAs (CN gain and
loss) and high-level CNAs (amplification and deletion) are shown as lighter and darker-colored
bars, respectively.
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Figure 1.17: Preferential inactivation of pRB in sub-cohorts of metastases.
(A) Mean phospho-RB IHC staining intensity and (B) proportion of phospho-RB+ cells in primarymetastatic tumor pairs arising in the same patient (top), or in different patients that were matched
by receptor status, tumor block age and preservation type (bottom). (C-E) Differences in mean
phospho-RB intensity in paired and matched (C) liver and non-liver metastases, (D) metastases
in patients with, or without, exposure to endocrine therapy, and (E) epithelial and stromal
compartments within tumors. Colored lines indicate the change in phospho-RB measures for
primary tumors compared with their paired or matched metastases (red = increase, blue =
decrease, 1-sided Wilcoxon signed-rank test).
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Figure 1.18: Co-occurrence of alterations in the mTOR and CDK/RB pathways.
(A-C) Patients whose primary tumors exhibited genomic alterations in either the mTOR or
CDK/RB pathways were more likely to give rise to metastases bearing genomic alterations in the
other pathway. Each column represents a primary-metastasis tumor pair from 1 patient. (A, B) CN
values (shaded bars) of STK11 and CDKN2A in primary (P) and metastatic (M) tumors from the
same patient ordered by CN values in the metastatic tumor. P-values indicate the degree of
correlation (univariate linear regression). (C) Primary tumors that harbored a non-PIK3CA
mutation in the mTOR Signaling pathway gene set (green, P) were more likely to give rise to
metastatic tumors with lower values of CDKN2A (blue, M) (2-sided Wilcoxon’s signed-rank test).
(D) High-level CNAs that are predicted to activate mTOR or inactivate pRB are correlated within
the total metastatic tumor cohort. Each column represents a metastasis from 1 patient. Blue bars
indicate tumors with STK11 deletion or CDKN2A deletion. Red bars indicate tumors with
amplification of PTK6, CCNE1, CDK2, CDK4 or CDK6. P-value indicates level of co-occurrence
of at least 1 mTOR-activating or pRB-inactivating CNA in tumors (green) (2-sided Fisher’s exact
test).
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Figure 1.19: Mutations in the WNT Signaling pathway gene set in metastases. Annotated
KEGG diagram indicating each gene mutated in the WNT Signaling pathway gene set within
metastases (red). All mutation frequencies are 1.5%, unless otherwise indicated.
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Figure 1.20: Preferential WNT activation and nuclear localization of activated PKA in
metastases. IHC analyses of β-catenin (A–C) and p-PKA (D–F) in primary (P) and metastatic (M)
tumors (n = 15). (A) Representative β-catenin IHC images for primary and metastatic tumors. (B)
Mean membranous β-catenin staining intensity and (C) proportion of nuclei that are β-catenin–
positive in paired and matched primary and metastatic tumors (1-sided Wilcoxon’s signed-rank
test). (D) Representative p-PKA IHC images for primary and metastatic tumors. (E) Mean
cytoplasmic p-PKA staining intensity and (F) proportion of nuclei that are p-PKA–positive in
paired and matched primary and metastatic tumors.
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Figure 1.21: Mutations in the cAMP Signaling pathway gene set in metastases.
Annotated KEGG diagram indicating each gene mutated in the cAMP Signaling pathway gene set
in metastases (red). All mutation frequencies are 1.5%, unless otherwise indicated.
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Figure 1.22: Mutations in the Focal Adhesion pathway gene set in metastases. (A)
Annotated KEGG diagram indicating each gene mutated in the Focal Adhesion pathway gene set
in metastases (red). All mutation frequencies are 1.5%, unless otherwise indicated. (B, C) Cooccurrence of mutations and alterations in the Focal Adhesion and mTOR Signaling pathway
gene sets. Bars indicate the presence of mutations or CNAs in paired primary tumors (P) and
paired metastases (M). (B) A large proportion of metastases exhibit mutations specific to the
mTOR Signaling pathway gene set and to the Focal Adhesion pathway gene set with trending cooccurrence (2-sided Fisher’s exact test). Tumors that only harbor mutations in genes that are
included in both pathways are in light green. (C) Primary tumors with a mutation in the Focal
Adhesion pathway gene set were more likely to give rise to metastases with STK11 loss (2-sided
Fisher’s exact test).
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Figure 1.23: Summary of genomic features implicated in metastases. Clinical and genomic
features of primary tumors (top) and metastases (bottom). From left to right: receptor subtype;
presence of mutations in primary tumor-associated SMGs, genes encoding ER, PR, and HER2,
and metastasis-specific SMGs; presence of low and high-level CNAs in known ‘driver’ genes for
primary breast cancer, metastasis-enriched CNAs, and additional genes whose encoded proteins
both inactivate pRB and exhibit trending enrichment in metastases. Far-right: presence of nonPIK3CA/TP53 mutations in SMPs and gene families (HKMTs) that are preferentially mutated in
metastases. Frequencies of each feature are given at the bottom for TCGA-BRCA primary tumors
as well as for primary and metastatic tumors in the present study. Mutation frequencies of SMGs,
clinical receptors, and pathways within TCGA-BRCA were calculated based on mutations recalled using the same variant calling pipeline employed in our study and variant thresholds
established in (3). Frequencies of low- and high-level CNAs in TCGA-BRCA result from a
GISTIC2 analysis reported by TCGA that used array competitive genomic hybridization assays
and per-sample CNA level cut-offs
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CHAPTER 2: RARE SUBCLONAL GENOMIC HETEROGENEITY WITHIN PRIMARY BREAST
CANCER DELINEATES THE HISTORY OF METASTATIC DISSEMINATION
2.1

Introduction
According to Laplacian determinism, all future states of a complex system can be

theoretically predicted if the resolution by which the current state is measured is sufficiently high.
Advances in genomic sequencing technology have made great strides to bring the study of breast
cancer - the leading cause of cancer related death amongst women (1) - closer to this Laplacian
ideal. First recognized by the association between the physical characteristics of tumors (e.g.,
size, pathology, lymphatic spread) and their behavior, the ability to predict clinical outcome and
treatment responses further improved when the measurement of a small number of molecular
makers by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) became
the standard of clinical care (109). For example, patients harboring tumors driven by amplification
of the HER2 oncogene are more likely to have metastatic relapse than patients whose tumors
lack HER2 amplification. Similarly, patients harboring tumors that are hormone receptor positive
(HRs: estrogen and/or progesterone receptor positive [ER+/PR+]) generally have a better
prognosis than tumors that are HR negative (110). Furthermore, tumors that lack either of these
drivers (so-called triple negative receptor breast cancer [TNBC]) tend to be more aggressive,
leading to worse overall survival in patients (111). To this end, prognostic accuracy has been
further improved by classifying tumors into molecular subtypes using higher resolution, pangenome molecular features, such as gene-expression (e.g., PAM50) (112) or copy number
alterations (CNAs) (e.g., IntClust) (39).
Despite this improved ability to associate genomic alterations with pathological
characteristics and prognoses, identifying mutations across the coding region of the genome
using whole-exome sequencing (WES) or targeted gene panels has revealed immense molecular
heterogeneity of tumors across patients (i.e. inter-tumor heterogeneity), even within specific
tumor subtypes (32). For example, relatively more, but not most, tumors of the IntClust1 copy
number (CN) subtype harbor mutations in GATA3 (113), suggesting that there may distinct
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pathways underlying cancer cell proliferation and survival even within highly defined tumor
subtypes. Similarly, despite rates of distant metastasis being higher for HR-/HER2+ tumors than
HR+/HER2- tumors (114), increased activity of the HER2 oncogene does not guarantee that any
given patient will recur, suggesting that other alterations may contribute to this process. It is thus
imperative to identify new features associated with metastasis and survival, and determine the
extent to which these features can be delineated within the earlier state of the cancer, the primary
tumor. To this end, retrospective studies have found that ESR1 activating mutations, which are
frequently selected for as a mechanism of treatment resistance to anti-estrogen targeted
therapies, can occur in <1% of cells within primary tumors based on digital droplet PCR (ddPCR)
(115, 116). Prospectively, the monitoring of circulating tumor cell DNA within the bloodstream
using ultra-deep sequencing (UDS) of mutations identified within the primary tumor (e.g., a
common activating PIK3CA mutation) has been shown to predict metastasis two years earlier
than clinical diagnosis (117).
The heterogeneity of molecular features across cellular subpopulations within tumors (i.e.
intra-tumor heterogeneity [ITH]) has itself been shown to be a predictor of clinical outcome.
Primary tumor ITH has been recognized as early as the first use of ER assessment during
pathological diagnosis, as tumors designated ER+ may exhibit as few as 1% of positive cells
(118, 119). It is now well known that breast tumors exhibit immense spatial and temporal
heterogeneity (120), with the principle lessons being that the assessment of one region within a
primary tumor is rarely representative of the entire tumor, nor the metastases that may
subsequently arise, and that ITH itself can be a prognostic biomarker. For example, diseasespecific survival is worse in patients with high ITH of ER expression (121) and high ITH of HER2
amplification (122). Similarly, variability in MYC, EGFR, and CCND1 CN values across singlecells within a primary tumor has also been shown to be significantly associated with the
probability of metastasis in TNBC patients (123). Furthermore, mutant allele tumor heterogeneity
(MATH), defined as the variation of allele frequencies across mutations as measured by WES
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(124), has been reported to be significantly associated with worse survival, both within and across
subtypes (125).
Despite the ability of WES to assess some of the heterogeneity present within tumors,
this technology cannot reliably detect mutations that occur within minor subclones (<50% of
tumor cells; cancer cell fraction [CCF] < 0.50) (126). While ultra-deep sequencing (UDS) has
allowed for higher detection power and more accurate variant allele frequencies (VAFs), UDS is
still hampered by sequencing noise, which can affect 5-10% of reads at any given site.
Additionally, it has become increasingly clear that published genomic datasets commonly contain
sequencing artifacts characteristic of the preservation method standardly used for primary
tumors, formalin-fixed paraffin-embedment (FFPE) (127). Specifically, these artifacts result from
the deamination of cytosine to uracil, which commonly occurs in FFPE-preserved tumors over
time. Thus, alternate methods are required to reliably detect clones that harbor mutations with
VAFs below the error-floor attributed to traditional sequencing technologies (126). One such
approach is provided by coupling UDS with unique molecular identifiers (UDS-UMI), whereby
errors and duplication events occurring after PCR amplification can be eliminated, and with uracilDNA glycosylase (UDG) treatment, which can mitigate a major source of FFPE artifacts (128).
In our previous study (129), WES and shallow whole-genome sequencing (sWGS) were
used to identify genes and pathways that were preferentially mutated and/or CN altered in
treatment-refractory, metastases compared with their paired primary tumors of origin (Chapter 1).
In this study, UDS-UMI, following FFPE-artifact mitigation by UDG treatment, was used in paired
primary and metastatic tumors to sequence commonly mutated sites as well mutations in
metastasis-enriched features that were classified as private (i.e., unique to the metastasis) by
WES. The resulting ultra-high depth to which these sites were sequenced in primary tumors
(~1300 unique molecules per site on average) permitted us to investigate intra-tumor genomic
heterogeneity present across exceedingly rare primary tumor subclones from which the history of
metastatic tumor outgrowth and dissemination could be reconstructed.
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2.2
2.2.1

Results
UDS-UMI dataset
Two custom panels (Qiagen QIAseq DNA V3) covering, in total, 203 12-bp regions of

interest (ROI) were sequenced using UDS-UMI to assay mutations at exceedingly low VAF within
clinically relevant receptors (ESR1, ERBB2, and PGR), known “hotspot” mutations within primary
tumors (e.g., PIK3CA E542K), as well as genes (e.g., PEAK1, XIRP2, MYLK) and pathways (e.g.,
mTOR, CDK/RB, WNT and cAMP/PKA signaling; focal adhesion and histone lysine
methyltransferase [HKMT] gene members) that we recently determined to be significantly and
preferentially mutated in metastases (129).
In total, 30 tumor blocks from 24 primary tumors and 14 tumor blocks from 13 of the 24
corresponding metastatic tumors were assayed. Receptor subtypes of assayed primary tumors (n
= 24) were as follows: HR+/HER2- (n = 19, 79.2%), HR-/HER2+ (n = 2, 8.3%), and HR-/HER2- (n
= 3, 12.5%). DNA was extracted from FFPE tumor blocks and treated with UDG prior to library
preparation to reduce the impact of FFPE-related sequencing artifacts. To confirm the ability of
UDG to reduce these artifacts, five samples were sequenced twice, with and without UDG
treatment. All primary tumors were preserved by FFPE. Eleven of the 14 assayed metastatic
tumor blocks were fresh frozen. After unique molecular tags (UMTs) were deconstructed from
sequenced reads, the median UMT coverage was ~1300x within primary tumors and ~400x in
paired metastases (see Methods).
2.2.2

WES validation
73 mutations previously called with high-confidence by WES were adequately covered in

the same assayed tumor block by UDS-UMI. Of these 73 mutations, 69 were also called by UDSUMI. 67 passed all filters by smCounter and two passed all but the “LowQ” (low base-quality rate)
filter, resulting in high- and low-confidence validation rates of 91.8% and 94.5%, respectively.
VAFs of validated mutations were highly correlated (β = 0.92, R2 = 0.77, P < 2.2E-16). Each of
the three mutations that were previously identified in FFPE samples by WES, but not by UDSUMI, were C>T/G>A mutations, which can result from cytosine deamination artifacts present in
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sequenced DNA extracted from FFPE tissue (130). Since UDG treatment was used to reduce the
impact of these artifacts in DNA sequenced by UDS-UMI, but not by WES, these apparent
mutations detected by WES, but not by UDS-UMI, likely represent FFPE sequencing artifacts.
2.2.3

Biological relevance of rare subclonal mutations
UDS-UMI enabled the detection of rare subclonal mutations, defined here as those that

occur under the VAF threshold standardly used in sequencing studies (VAF < 0.10, CCF ≲ 0.20).
These mutations were present in as little as 0.6% of cells within the primary tumor (CCF min =
0.0057, median = 0.036, IQR = 0.020 – 0.063) and were surprisingly frequent. Within primary
tumors, a median of 1.08% of genomic sites exhibited rare subclonal mutations (IQR = 0.88 1.52%). This rare subclonal mutation burden (RMB) was investigated to determine the biological
significance of genomic ITH across rare subclones that is independent of driver mutations highly
represented within primary tumors.
RMBs within primary tumors were significantly associated with increased average UMT
coverage (one-sided univariate regression, P = 0.020; one-sided multivariate regression, P' =
0.015) and tended to be higher in older tumor blocks (P = 0.13, P' = 0.083) (Figure 2.1A). After
down-sampling sequencing data to reduce variability in total UMT coverage, RMB was no longer
positively associated with the residual variability in UMT coverage (P = 0.92, R2 = 0.09; P' =
0.83). In this data set, rare subclonal mutations were detected in as few as 0.8% of cells (CCF
min = 0.0084, median = 0.058, IQR = 0.038 – 0.13), resulting in a median RMB of 0.49% (IQR =
0.28 - 0.74%). RMB remained positively correlated with tumor block age (P = 0.0011, R2 = 0.35;
P' = 0.0025; Figure 2.1B). The observation that 35% of the variability in RMB can be explained by
its association with tumor block age suggests that a proportion of rare subclonal mutations can be
attributable to FFPE-artifacts, which increase in frequency within tumor blocks over time.
Down-sampled UDS-UMI sequencing data revealed decreased RMBs within metastases
(median of 0.15%, IQR = 0.14 - 0.19%) compared with primary tumors; however, a direct
comparison of RMBs between primary and metastatic tumors is precluded by the confounding
variables of preservation type (all primary tumors blocks were FFPE, whereas only 3 of 14
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metastatic tumor blocks were FFPE), and tumor block age (all primary tumors blocks were older
than all, but one, metastatic tumor block).
Only 26 of 546 (4.8%) rare subclonal mutations called in 5 untreated samples were also
called in the same samples following treatment with UDG, in which only 61 rare subclonal
mutations were called. UDG treatment thus resulted in the depletion of FFPE artifacts by at least
88.8% based on a highly conservative assumption that all rare subclonal mutations result from
FFPE artifacts.
A relatively large proportion of rare subclonal mutations were shared across multiple
tumor blocks assayed from the same tumor (11 tumor blocks from 5 primary tumors, median
proportion shared = 37.5%, IQR = 30.3 - 51.0%). Although the proportion of shared mutations
between related tumor blocks was significantly higher than between unrelated tumor blocks (P =
0.024, one-sided Wilcoxon rank-sum test), the proportion of mutations shared between unrelated
tumor blocks was unexpectedly high (median = 28.4%, IQR = 18.8% - 38.5%). Interestingly,
mutations that were shared between unrelated tumors were significantly enriched for mutations
present in the cancer somatic mutation database, COSMIC, compared with mutations that were
not shared (25.8% vs 12.7%, respectively, one-sided Fisher’s exact test, P = 0.0062). Together,
the greater extent of overlap of mutations identified in related, compared with unrelated, tumor
blocks, as well as the enrichment for previously reported somatic mutations in cancer amongst
mutations that were shared between unrelated tumor blocks, provide evidence that rare subclonal
mutations are biologically relevant and do not primarily arise from sequencing noise and/or FFPE
artifacts.
2.2.4

Primary tumor RMB is associated with alterations driving tumorigenesis
After controlling for variability in UMT coverage via down-sampling, primary tumors

classified as stage II-IV at diagnosis exhibited significantly higher RMBs than stage I primary
tumors (one-sided Wilcoxon rank-sum test, P = 0.0072, one-sided multivariate logistic regression
controlling for tumor block age, P' = 0.035; Figure 2.2). This suggests that increased intratumoral
heterogeneity is associated with more advanced stage. Thus, RMB may increase naturally over
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time within primary tumors or is, perhaps indirectly, associated with increased tumor
aggressiveness. Notably, an association between RMB and relapse free survival (RFS) was not
found, possibly due to the confounding, direct proportionality of tumor block age with RFS
resulting from metastatic patients being enrolled in the study within a similar time period.
Therefore, we instead sought to determine whether RMB was associated with the
presence within primary tumors of specific genomic alterations that are either known drivers of
breast cancer primary tumorigenesis or are enriched in treatment-refectory metastases
(129)(Figure 2.3). This analysis revealed that RMBs were increased in primary tumors that harbor
breast cancer associated CNAs: loss of TP53 (P = 0.035, P' = 0.13) and MAP2K4 (P = 0.062, P'
= 0.15); and gain of CCND1 (P = 0.084, P' = 0.044) and PIK3CA (P = 0.11, P' = 0.012). In
contrast, RMB was not significantly associated with mutations in either PIK3CA (Pf = 0.22, Pf' =
0.11) or TP53 (Pf = 0.83, Pf' = 0.51), which is consistent with mutations in PIK3CA and TP53
being initiators of tumorigenesis and thus arising before the tumor was heterogeneous.
Aggregating associations (Fisher’s method) across all tested breast cancer-associated CNAs (n =
12 tests, see Methods) demonstrated that RMB is significantly associated with an increased
number of CNAs (Pf = 0.074 and Pf' = 0.018) within the 12 genes tested. Supporting the biological
relevance of this conclusion is the finding that there is no association between RMBs and CNAs
when the reverse CN directions (e.g., TP53 gain) were tested and aggregated (Pf = 0.81, Pf' =
0.27). This, in turn, supports the conclusion that RMB is a biologically relevant biomarker and not
simply an indicator of increased CN burden.
Interestingly, associations were also found between primary tumor RMB and the
presence within primary tumors of genomic alterations that we previously reported to be enriched
in metastases: gain of PTK6 (P = 0.038, P' = 5.3 × 10-4), gain of PAQR8 (P = 0.068, P' = 0.0040)
and mutation within an HKMT (P = 0.035, P' = 0.056). Thus, primary tumor RMB is associated
with metastasis-enriched features within the primary tumor when controlling for tumor block age
(n = 13 tests, Pf = 0.27, Pf' = 0.013).

74

2.2.5

Primary tumor RMB predicts acquisition of alterations enriched in metastasis
More intriguingly, the paired nature of this dataset allowed us to reveal that primary tumor

RMB was associated with the subsequent acquisition – within paired metastases – of a variety of
metastasis-enriched genomic alterations (129), both in aggregate across all metastasis-enriched
features tested (Pf = 1.0 × 10-5, Pf' = 0.0081, n = 13), and with respect to multiple independent
genomic alterations, including: ERBB2 gain (P = 0.0055, P' = 0.0053); PTK6 gain (P = 0.0056, P’
= 0.011); an increased number of CNAs that are estimated to inactivate pRB (P = 0.011, P’ =
0.088); and newly acquired mutations in the mTOR (P = 0.0050, P’ = 0.060), WNT (P = 0.0081,
P’ = 0.061), focal adhesion (P = 0.031, P’ = 0.091), and cAMP (P = 0.032, P’ = 0.12) signaling
pathways.
Strikingly, RMB was also significantly higher in primary tumors whose metastases
exhibited a larger proportion of nuclei that stain positive for activated pPKA (P = 0.0022, P' =
0.014), a pattern of localization that is specific to metastases and is indicative of activated
cAMP/PKA signaling (129). Together, these associations suggest that primary tumors with
increased rare subclonal genomic heterogeneity (as indicated by RMB) are more likely to exhibit
– or acquire during metastasis – genomic alterations that underlie metastasis and/or resistance to
therapy.
2.2.6

Other covariates of primary tumor RMB
Relationships between RMB and measures of homologous repair deficiency were also

analyzed (data not shown). Associations were not found between RMB and the frequency of
large-scale loss of heterozygosity events, nor with the number of large-scale state transitions
across the genome. However, RMB within primary tumors was significantly associated with the
degree of allelic imbalance (AI) within primary tumors (P = 0.20, P' = 0.014) and within their
paired metastases (P = 0.11, P' = 0.0035). Along with the observation that metastases exhibited
a trending increase in AI compared with their paired primary tumors (p = 0.085, n = 28), these
findings suggest that primary tumor RMB may, in part, be indicative of genomic instability in
primary tumors and predictive of increased genomic instability in metastases.
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Importantly, RMB was not associated with patient age at primary tumor diagnosis,
suggesting that this biomarker is not simply a marker for age-related effects (P = 0.55, P' = 0.72).
RMB was also not associated with estimated tumor purity within either primary or metastatic
tumors (P = 0.42 and 0.37, and P' = 0.65 and 0.59, respectively), suggesting that associations
observed between primary tumor RMB and genomic features do not result from a differential
ability to detect alterations as a consequence of differences in tumor purity. Similarly, removing
from the analysis rare subclonal primary tumor mutations that occurred at high allele frequency
within their corresponding metastases did not substantially affect the significance of the observed
association with metastasis-enriched genomic features, indicating that the operative feature is
RMB and not the specific mutations themselves, which could increase RMB. Finally, an
association between RMB and receptor subtype was not found, although the power to detect
such an association was potentially limited by the abundance of HR+ and HER2- tumors in this
dataset (88% and 92%, respectively). Despite this, an association between RMB and ERBB2 CN
gain in metastases was able to be found due to a subset of HER2- tumors that harbored low-level
CN gains of ERBB2 below the standard clinical threshold (CN ≥ 4) used to determine HER2
positivity.
2.2.7

Delineated History of “Metastasis-specific” Mutations
131 “metastasis-specific” mutations previously identified by WES in metastatic tumors –

but not in their paired primary tumors – were adequately covered by UDS-UMI in at least one
tumor block of the originating primary tumor. In total, 27 blocks from 21 primary tumors were
assayed. Additionally, DNA from multiple regions of the same primary tumor were sequenced to
assay metastasis-specific mutations. Specifically, ten metastasis-specific mutations were
assayed in two blocks each and two metastasis-private mutations were assayed in three blocks
each. The median UMT coverage of metastasis-specific mutation sites in primary tumors was
1,288x (IQR = 674 – 2,657x). Within metastases (n = 11), all adequately covered metastasisprivate mutations were called with high-confidence by UDS-UMI (n = 29).
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As applied here, UDS-UMI had 95% power to detect - with high-confidence - mutations
that were present at each of the sites in as few as 0.27% of tumor cells (minCCF95% min = 0.0027,
median = 0.027 [IQR = 0.016 – 0.048]). Despite this, 111 of the 131 (85%) metastasis-specific
mutations assayed remained undetected in their corresponding primary tumors. Mutations that
were detected within a metastasis, but not within its paired primary tumor, included those within
genes encoding clinical receptors (ESR1, ERBB2, PGR), genes frequently mutated in breast
cancer (PIK3CA, TP53, KMT2C, AKT1), genes that are frequently and preferentially mutated in
metastases (XIRP2, PEAK1, MYLK), and genes that are components of signaling pathways that
are frequently and preferentially mutated in metastases (TSC1, RICTOR, RB1, CCND1,
WNT1)(129)(Figure 2.4). Seven metastasis-specific mutations (ESR1 D540G and V424del,
XIRP2 G1349E, JAK3 L618P, ITGB4 D943Y, RAPGEF4 V41A, and HSPA8 start-lost) failed to be
detected despite being assayed for in two different tumor blocks and two metastasis-specific
mutations (PIK3CA E545K, USH2A H2706N) failed to be detected despite being assayed for in
three different tumor blocks.
Of the 20 metastasis-specific mutations detected in primary tumors by UDS-UMI, nine
(JAK1 G902V, LRP5 A65V, PEAK1 K140Q, CD14 E209K, COL4A2 R1410Q, SETD1B E945K,
TGFBRAP1 S626F, splice-site mutations in RAPGEF4 and HSPG2) were called with highconfidence by UDS-UMI as being within rare subclones of the primary tumor. In total, 6 out of 24
(25%) primary tumors exhibited at least one metastasis-specific, rare subclonal mutation, with
three tumors (12.5%) exhibiting two metastasis-specific, rare subclonal mutations. Three
metastasis-specific, rare subclonal mutations were detected in only one of two primary tumor
blocks assayed, suggesting that the assessment of more regions of a primary tumor should
reveal more metastasis-specific present within rare primary tumor subclones.
Based on background RMB and total number of mutations assayed for each patient, it is
unlikely (probabilities < 20%, Table 2.1) that these rare subclonal mutations were detected by
chance in their respective primary tumors. Indeed, the combined probabilities that at least one
mutation was detected by chance in at least six patients, and that at least two mutations were
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detected by chance in at least three patients, were 0.0041 and 6.9e-04, respectively.
Furthermore, on an individual tumor basis, the probability that mutations were detected by chance
achieved significance in one primary tumor (patient P25, P = 0.00026) and trending significance
in two others (patient P52, P = 0.058; P11, P = 0.078). When metastasis-specific mutations were
instead investigated in unrelated primary tumors, at least 6 unrelated primary tumors exhibited at
least one metastasis-specific mutation in only 4.2% of permuted datasets. Similarly, at least 3
unrelated primary tumors exhibited at least two metastasis-specific mutations in only 2.0% of
permuted datasets. In summary, detected metastasis-specific mutations likely resulted from true
minor subclones within the primary tumors, and not from multiple independent mutation events or
sequencing/FFPE artifacts.
In contrast to the power afforded by UDS-UMI, WES was only able to reliably call
mutations at these 131 sites that occur within major sub-clones (defined as CCFMAP ≥ 0.50):
minCCF95% = 0.54 [0.41 – 0.72]. Even then, 11 of the 20 metastasis-specific mutations detected in
the corresponding primary tumor by UDS-UMI occurred at high VAF (≥ 0.10) and clonality (med
CCF = 0.95 [IQR = 0.77 – 1.04], min = 0.59). The presence of each of these mutations in primary
tumors was originally suggested by WES, but did not reach various filtering thresholds (low
coverage, low number of variant reads, or insufficient number of callers in consensus). The failure
to reliably detect these mutations using WES underscores the limited power of WES to identify
mutations that occur even within major subclones within primary tumors.
Together, these results show that the majority of mutations deemed private in metastases
by WES were not found in corresponding primary tumors, suggesting that these mutations either
arose after metastatic tumor dissemination, were present in fewer than 2.7% of cells, on average,
within the primary tumor (the detection confidence threshold attributable to UDS-UMI), or
occurred within unassayed regions of the primary tumors. However, UDS-UMI was able to
identify, in a subset of patients, rare primary tumor subclones that harbored metastasis-specific
mutations, which likely did not result from multiple independent mutation events or FFPE artifacts.
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2.2.8

Reconstructed histories of metastatic dissemination
Metastasis-specific, rare subclonal mutations detected within primary tumors occurred in

as few as 2% of primary tumor cells (CCFMAP min = 0.02, median = 0.080, IQR = 0.035 – 0.151,
max = 0.276; VAF min = 0.005, median = 0.022, IQR = 0.009 – 0.039, max = 0.087). The
estimated range of CCFs for these mutations in both primary and metastatic tumors, across
potential multiplicity factors (s, defined as the possible number of alleles for which the mutations
may be present), enabled the reconstruction of the history of metastatic dissemination (Figure
2.5)
In patient P65, the JAK1 G902V mutation, which was present in a minor sub-clone within
the primary tumor (for s = 1, CCFMAP = 0.37; for s = 2, CCFMAP = 0.18), was estimated to be clonal
within the metastatic tumor using both possible multiplicity factors (for s = 1, CCFMAP = 1.94; for s
= 2, CCFMAP = 0.97). This suggests that all cells in this patient’s metastasis descended from one
or more cells disseminated from a JAK1-mutant minor subclone present within the primary tumor.
In patient P25, two mutations that were previously deemed private to their synchronous
metastasis were subsequently identified by UDS-UMI in subclonal populations within the paired
primary tumor: LRP5 A65V (s = 1, CCFMAP = 0.02), and PEAK1 K140Q (s = 1, CCFMAP = 0.24).
Since the sum of the CCF distributions of these mutations in the metastasis (s = 1, CCFMAP =
0.81 and 0.65, respectively) is significantly greater than one (P = 1.74e-06, see Methods), it can
be deduced via the pigeonhole principle that this metastasis was seeded by a subclone bearing
both mutations. Furthermore, since neither mutation is likely to be clonal in the metastasis
subclonal probability, PCCF < 1 ≥ 0.99), it can also be deduced that this metastasis arose from at
least one other primary tumor clone that was wild type for these mutations (i.e., polyclonal
dissemination).
Similarly, in patient P52, two ‘metastasis-specific’ mutations were identified in the
corresponding primary tumor. Within the two metastatic tumor blocks assayed, the HSPG2
mutation was estimated - with high-confidence - to be subclonal (PCCF < 1 = 0.98 and 0.90), and
the RAPGEF4 mutation showed evidence of subclonality in one of two metastatic tumor blocks
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assayed (PCCF < 1 = 0.89 and 0.34), suggesting that this metastasis originated from polyclonal
dissemination. Although ambiguity regarding multiplicity factors precluded the ability to determine
- with high confidence - that these mutations co-occurred within the same subclone, we consider
this possibility likely (18 out of 21 combinations of multiplicity factors result in CCF sums greater
than 1). For the remaining three patients (P11, P12, P26), mono- vs. polyclonal dissemination
could not be confidently determined due to ambiguity regarding multiplicity factors. Nevertheless,
there was some evidence of polyclonal dissemination for primary tumors P26 and P12 since at
least one metastasis-specific mutation identified in each of these primary tumors was borderline
subclonal in at least one corresponding metastatic tumor block (P26: PCCF < 1 = 0.91; P12: PCCF < 1
= 0.92).
2.3

Discussion
As a consequence of the limitations of sequencing technologies typically used for clinical

genomic studies, investigations into genomic alterations that drive primary tumorigenesis,
metastasis and therapeutic resistance predominantly focus on clonal or high VAF events. The
resulting snapshot provides a relatively low resolution, borderline dichotomous (i.e., a mutation is
detected within a metastasis, but not its corresponding primary tumor) understanding of the
genomic events that drive metastatic evolution. This study sought to increase the resolution with
which the evolutionary histories of metastases can be delineated in order to more effectively
implicate molecular drivers of metastasis that occur in rare subclones within primary tumors. To
this end, UDS-UMI coupled with UDG treatment allowed for the quantification of rare subclonal
genomic ITH present within primary breast cancers, and to trace the acquisition, or lack thereof,
of metastatic drivers within rare primary tumor subclones.
In particular, this study demonstrates that UDS-UMI coupled with UDG treatment can
identify mutations in as few as 0.6% of cells, and provides evidence that the majority of these
mutations represent bona fide mutations, rather than sequencing artifacts. Our findings also
reveal that rare subclonal genomic ITH (as determined by RMB) is higher in more advanced
stage primary tumors and in primary tumors that harbor increased frequencies of a subset of
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alterations associated with primary tumorigenesis (gain of PIK3CA and CCND1 and loss of TP53
and MAP3K1). Furthermore, high primary tumor RMB was associated with the presence in
primary tumors of genomic alterations that we have previously found to be enriched within
metastases: gain of PTK, gain of PAQR8, and mutation within an HKMT. These findings suggest
that primary tumor RMB is associated with the presence of metastasis-associated genomic
features within the primary tumor, and further suggest the biological relevance of RMB as a
biomarker for intratumoral heterogeneity.
Strikingly, elevated rare subclonal genomic ITH present within primary tumors was
strongly associated with the acquisition within the corresponding metastases of genomic
alterations that have been implicated in metastatic breast cancer progression: gain of ERBB2 or
PTK6; the number of pRB-inactivating CNAs; newly acquired mutations in the mTOR, WNT, focal
adhesion, and cAMP signaling pathways; and the frequency of cells with nuclear localization of
activated PKA (129). Together, the observation that increased intratumoral heterogeneity within
rare primary tumor subclones, as reflected by elevated RMBs, is associated with advanced tumor
stage as well as the acquisition of genomic features characteristic of metastasis suggests that
heterogeneity within rare primary tumor subclones may contribute to metastatic progression, and
provides further support for the biological relevance of RMB as a biomarker.
In addition to these insights, UDS-UMI also provided a unique opportunity to delineate
the evolutionary history of mutations contributing to breast cancer metastasis. Indeed, nine
mutations (JAK1 G902V, LRP5 A65V, PEAK1 K140Q, CD14 E209K, COL4A2 R1410Q, SETD1B
E945K, TGFBRAP1 S626F, splice-site mutations in RAPGEF4 and HSPG2) initially deemed to
be private to metastases based on WES data were subsequently determined by UDS-UMI to be
present in rare subclones within the originating primary tumor. These rare subclones were
comprised of as few as 2% of tumor cells and were identified within the primary tumors of six of
24 patients, suggesting that this evolutionary history of metastasis originating from very rare
subclones is not uncommon. Likelihood and permutation analyses revealed that metastasisspecific mutations that were identified in rare primary tumor subclones likely were bona fide
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mutations and not a result of sequencing artifacts or multiple independent mutation events. Based
on the estimated proportion of cells bearing these mutations in paired primary and metastatic
tumors, this approach was able to confidently reconstruct histories of monoclonal dissemination in
one patient and polyclonal dissemination in two patients, as well as provide evidence to support
histories of polyclonal dissemination in two additional patients. As these mutations would not
have been considered truncal in an analysis of WES/WGS mutations, our findings reveal that
higher resolution, error-mitigated UDS-UMI technology improves the confidence with which the
histories of metastatic tumor dissemination can be reconstructed.
Notably, the identification of “metastasis-specific” mutations within rare subclones in
primary tumors implicates these particular mutated genes not only as markers for rare subclones
that gave rise to metastases following their dissemination, but also as potential drivers of
metastasis and/or treatment resistance. Supporting this inference is our finding that mutations in
two genes, LRP5 and PEAK1, with putative roles in metastatic breast cancer appeared to be
present within the same rare subclone (2% of tumor cells) in the primary tumor that likely seeded
a metastasis in that patient. LRP5 activates canonical WNT signaling through its role as a coreceptor with LRP6 and Frizzled family members and is directly inhibited by DKK1. Based on its
structural similarity to the known LRP5 E171V activating mutation, Bhat and colleagues (48) first
predicted and then showed that the LRP5 A65V mutation identified in our study confers enhanced
resistance to its inhibition by DKK1, thereby activating canonical WNT signaling. PEAK1, in turn,
is involved in regulating focal adhesions and cell migration and is one of seven SMGs that we
found to be preferentially mutated in metastases (129). Due to an overall decrease in PEAK1 CN
in metastases compared with primary tumors, as well as the observation that five of the six
PEAK1 mutations that we identified in metastases are deleterious (2 nonsense, 3 missense that
co-occur with CN loss), we previously hypothesized that PEAK1 loss of function is selected for
during metastatic progression. Together, these observations raise the intriguing hypothesis that
the ability of this rare primary tumor subclone to seed a metastasis was influenced by the LRP5
A65V and PEAK1 K140Q mutations contained within it. Furthermore, the fact that the
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corresponding metastasis in this case was synchronous (discovered 9 days after primary tumor
diagnosis), suggests that these mutations specifically enhance metastatic potential rather than
treatment resistance. Together, these findings enabled by the UDS-UMI approach employed in
this study, coupled with delineation of the mutation selection history in this patient, supports the
hypothesis that canonical WNT pathway activation coupled with PEAK1 inactivation promote
metastatic dissemination and/or outgrowth.
Although prior studies have delineated some metastatic tumor mutations within their
originating primary tumors, several aspects of the technological approach employed in this study
enabled further insights into the role primary tumor genomic ITH plays in treatment resistance
and metastasis. Indeed, a principle conclusion of this study is that UDS alone is insufficient to
accurately identify rare subclonal mutations. Rather, UMI technology is needed to distinguish
sequencing artifacts and noise that occur after DNA amplification from genuine variants, and
UDG treatment of DNA extracted from FFPE tumor blocks is required to mitigate artifacts that
commonly result from the standardly used FFPE preservation method. For example, while deep
sequencing performed following WES in a study of paired breast metastases (11) allowed for
more accurate estimates of mutation clonality and provided increased power to detect mutations
within primary tumors compared to WES alone, this approach was unable to detect rare subclonal
mutations that occur beneath the error-floor attributed to standard sequencing approaches (510% of reads). Analogously, although droplet digital PCR (ddPCR) is generally considered to be
the gold-standard for identifying rare subclonal mutations, only one or two mutations can typically
be assayed at a time, thereby impairing the practicality of its use for surveying a broad range of
mutations. Additionally, the high frequency of mutations that we have shown to occur in rare
subclones suggest the possibility that any given “metastasis-specific” mutation found in a primary
tumor rare subclone by ddPCR may have resulted from multiple independent mutation events. In
contrast, the assessment of 2,436 bps in several patients in tandem by UDS-UMI employed in
this study afforded the ability to estimate the probability that an identified mutation resulted from
multiple independent mutation events or a sequencing artifact.
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Despite these strengths, our study has several limitations. For example, a fundamental
limitation of studies of the genomic evolution of cancer is sampling error; namely, the inability to
comprehensively assay all regions within primary and metastatic tumors analyzed. Accordingly, a
“metastasis-specific” mutation that is in actuality present in the corresponding primary tumor may
nevertheless go undetected, due either to spatial heterogeneity within the tumor or the small size
of the subclone. Similarly, the clonality of a particular mutation in an assayed tumor block may not
be representative of the tumor as a whole. In either case, assaying a greater number of regions
within the tumor would result in improved estimates for clonality, along with the models based
upon them. An additional limitation of our study is that our metastatic cohort consisted primarily of
patients who had previously been treated. Accordingly, metastases with and without exposure to
therapies (both targeted and non-targeted) would be needed to deconvolute the roles of rare
subclonal genomic ITH in treatment resistance and metastasis per se. Further, since only coding
regions were assayed in our study, mutational processes occurring exclusively in intergenic
and/or intronic regions could not be identified. An additional limitation arises from the fact that our
study restricted sequencing to regions of the genome that were known to be mutated in at least
one tumor; this may have inadvertently inflated estimated rates of rare subclonal mutation within
primary tumors. Finally, while UDG treatment was estimated to have removed >88% of FFPE
sequencing artifacts, complete elimination of these artifacts was not achieved. Thus, future
studies would benefit from inclusion of a panel of matched fresh-frozen primary tumor blocks for
validation.
2.4
2.4.1

Methods
Metastasis-specific mutations
WES and sWGS methods employed in Chapter 1 were used to identify mutations that

were private to metastasis and their respective clonality estimates, and thus not present in the
originating primary tumor. Mutations were determined to be “metastasis-specific” mutations if they
were categorized as tier I in the metastatic tumor, but not tier I in the corresponding paired
primary tumor. In this study, germline coverage and putative germline variants were determined
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at all sites within ROIs using samtools “mpileup” (v1.3.1, parameters: -t AD -Q 10) and bcftools
“call” (v1.2, parameters: -AmO v) from WES of corresponding buffy coat blood samples. Variants
with coverage ≥ 6, AAC ≥ 3, and VAF ≥ 0.25 were considered germline. Copy number alterations
were segmented using QDNAseq (97) and were normalized by estimated tumor ploidy and
cellularity, which were estimated by Sequenza (108).
2.4.2

Ultra-deep sequencing with unique molecular indices
Primers were designed and generated using Qiagen QIAseq DNA V3 Panel Analysis.

DNA samples were treated with UDG prior to library preparation to reduce the impact of FFPErelated sequencing artifacts. To confirm the ability of UDG to reduce FFPE-related artifacts, five
samples were sequenced twice, with and without UDG treatment. Libraries were prepared
manually per manufacturer instructions and sequenced on a NextSeq 500 using 150 bp pairedend reads. Raw reads were aligned to hg19 and variants were called using smCounter (131) as
implemented in Qiagen’s GeneGlobe Data Analysis Center. For panel #1, ROIs were sequenced
to a median coverage of 32,484x (average reads per ROI, interquartile range [IQR] = 6,175 40,441x) in primary tumors and 984x (IQR = 521 - 1,798x) in metastatic tumors. From these
sequenced reads, the median unique molecular tag (UMT) coverage was 1,283x (IQR = 792 2,503x) for primary tumors and 406x (IQR = 242 – 553x) for metastases. Panel #2 prioritized
metastasis-specific mutations and was used to assay a subset of primary tumor blocks assayed
in panel #1 (11 tumor blocks from 10 primary tumors). For panel #2, ROIs were sequenced to
median coverage of 133,731x (IQR = 97,100 – 202,547x), resulting in the median UMT coverage
per ROI of 1,314x (IQR = 1006 – 3,207x). Variants that passed all default filters by smCounter
and were not estimated to be germline by WES were considered high-confidence (min AAC = 4).
Loci not covered by at least 100 UMTs by UDS-UMI and by at least six reads in corresponding
normal samples by WES were excluded from analysis. Variants with VAF < 0.10 were considered
rare subclonal mutations. RMB was determined by dividing the total number of high-confidence
rare subclonal mutations by the total number of highly covered ROI sites, and was limited to
panel #1.
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2.4.3

Covariates of RMB
Multivariate linear regression was used to determine whether the increased presence of

rare subclonal mutations could be explained by features of tumor blocks (e.g. tumor block age)
and sequencing (e.g. mean UMT coverage), using: RMB = tumor block age + mean UMT
coverage. Due to the finding that RMB is significantly correlated with mean UMT coverage, raw
read files (fastqs) were down-sampled based on average ratios of UMT:Total read coverage to
approximately match the mean UMT coverage of the least covered sample. This resulted in
median mean UMT coverage of 576x (IQR = 439 – 731x).
Within this down-sampled cohort, RMBs – within primary tumors – were investigated to
determine whether they were correlated with the presence of genomic features, including CNAs,
mutations, and IHC assay data, in either paired primary and metastatic tumors. This analysis
included CNAs that are known to be involved in primary tumorigenesis (loss of TP53, RB1,
MAP2K4, KMT2C and PTEN; gain of PIK3CA, ERBB2, CCND1, EGFR, and FOXA1), as well as
those that we determined are enriched in metastases (gain of PAQR8 and PTK6; loss of
CDKN2A and STK11)(129). The number of high-level CNAs anticipated to inactivate pRB
(deletion of CDKN2A or RB1, amplification of CCND1, CCNE1, CDK1, CDK2, CDK4, or CDK6)
within tumors was also included as feature, based on our observation that metastases exhibit a
significant increase in these alterations (129). Mutations considered included those in PIK3CA,
TP53, and the metastasis-enriched KEGG genesets: mTOR Signaling, cAMP Signaling, WNT
Signaling, and Focal Adhesion pathways, as well as at least one mutation within an HKMT within
the Lysine Degradation pathway. When testing the association of primary tumor RMB with
mutations in these pathways in metastases, only private mutations (i.e., those not shared with the
originating primary tumor when assayed by WES) were included. Finally, IHC staining patterns
that were preferentially identified in metastases (129) were also included as features, including
increased intensity of phospho-S6, increased intensity of membranous beta-catenin, decreased
intensity of phospho-RB, and increased proportion of cells that exhibited nuclear phospho-PKA
staining. Tumor block age, which was a significant covariate of RMB in this down-sampled set,
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was used as a covariate within the one-sided multivariate linear and logistic regressions. The
Benjamini-Hochberg method was used for multiple testing correction.
2.4.4

Cancer cell fraction and detection power
A Bayesian approach was used to estimate the proportion of tumor cells in which a given

mutation was present (cancer cell fraction, CCF) based on total read coverage, AAC, tumor
cellularity, locus-specific CN, and estimated number of mutated alleles (a.k.a multiplicity factor, s)
for that mutation (132). Calculating the CCF using a binomial distribution dependent on the
number of reads (WES) or UMTs (UDS-UMI) covering the alternative allele and the
aforementioned locus-specific parameters permits the uncertainty of the mutation CCF estimate
to be modeled. The CCF with the highest likelihood (“maximum a posteriori”, CCFMAP) are
provided throughout. The multiplicity factor required for this approach cannot be measured and is
often heuristically chosen. Some studies set this parameter for every mutation to 1 (i.e., only one
allele is expected to contain the mutation) or to the largest possible value (the CN of the major
allele), which lead to CCF estimates that are biased towards either higher values or zero,
respectively. In this analysis, as a compromise, the multiplicity factor was set to the median of all
possible multiplicity factors from 1 to major CN, which is estimated by Sequenza, such that:

C = DEF G

DHIJEK( 1 MN DEONPQR )
× PHSEMJTH QR × USNJIV, 1W
DEONPQR + DJKNPQR

QQXYZ[ = DEF\\] ^JKNDJES(F = __Q, K = QNTHPE`H, a = U)
U=

(bHSScSEPJMV × bbd × C)
(1 − bHSScSEPJMV) × 2 + bHSScSEPJMV × USNJIV × PHSEMJTH QR

The smallest CCF for which there was ≥95% power to call a mutation with highconfidence, minCCF95%, was estimated for both WES and UDS-UMI to determine an upperbound on the clonality of a theoretically undetected mutation. For example, for an undetected
mutation, cells harboring this mutation were either not present in the region of the tumor that was
assayed or were present in a sufficiently small number of tumor cells to have not been detected
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by sequencing. Accordingly, minCCF95% provides a measure for how large a clone must be in
order to reliably detect a mutation residing within it. minCCF95% was calculated by identifying the
smallest CCF for which the cumulative distribution function of the above equation was ≥95%,
where the number of theoretical alternative reads required for a mutation to be called by WES
was 10% of the total coverage at that locus (min = 6). The number of theoretical alternative reads
required for UDS-UMI was dependent on the total number of UMTs sequenced and was
conservatively estimated as a step-wise function based on the minimum AAC of high-confidence
mutations called by smCounter: UMTs < 453: AAC = 4, UMTs < 753: AAC = 5, UMTs < 1,196:
AAC = 6, UMTs < 2,090: AAC = 7, UMTs < 2,820: AAC = 8, and UMTs ³ 2,820: AAC = 9.
2.4.5

Rare subclonal mutation detection probabilities
The probabilities that one, or two, metastasis-specific mutation(s) were called in

corresponding primary tumors by chance were estimated using a binomial test, where p = RMB
and n = the total number of sites (bps) highly covered by UDS, where both n and p exclude ROIs
that assay metastasis-specific mutations in that given sample. The combined probabilities that at
least one metastasis-specific mutation was detected by chance in six patients and at least two
metastasis-specific mutations were detected by chance in three patients was estimated by taking
the sum of the products of individual detection probabilities over all possible combinations of
detected patients. Permutation p-values were generated by finding the number of times at least
one metastasis-specific mutation was detected in at least six permuted (i.e., non-related) primary
tumors and the number of times at least two metastasis-specific mutations were detected in at
least three permuted primary tumors from 10,000 permutations of sample labels.
2.4.6

Models of evolution
Modes of evolution can be inferred from the CCF distribution of mutations shared

between primary and metastatic tumors. Subclonal probability, PCCF < 1, is determined by taking
the sum of the probabilities for CCF values < 1, with PCCF < 1 ³ 0.95 indicating a likely subclonal
mutation. A mutation can be considered clonal if the CCFMAP is close to 1 and the subclonal
probability is not significant. A mutation that is likely subclonal in both primary and metastatic
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tumors in at least one tumor block suggests that the metastasis resulted from more than one
subclone from the primary tumor (polyclonal dissemination). The presence of a subclonal
mutation in the primary tumor and a clonal mutation in the metastatic tumor is indicative of
monoclonal dissemination, in which all disseminated cells harbor the mutation. Note that this
does not rule out the presence of additional subclones that are heterogeneous for other
mutations.
Two mutations can be estimated via the pigeonhole principle to be within the same
subclone if, for every pairwise combination of multiplicity factors, the sum of their CCF
distributions are significantly greater than one. In this case, the CCF sum was determined by
constructing a normal distribution with the mean being the sum of means of the separate CCF
distributions and variance being the sum of variances of the separate CCF values. If 95% of the
resulting normal distribution is greater than one, the mutations likely co-occurred within the same
subclone. In several cases, ambiguity in multiplicity factors precluded the ability to estimate
polyclonal vs. monoclonal distribution, or whether mutations co-occurred within subclones due to
mutations being equally like to occur in subclonal or clonal populations.
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Figure 2.1: Characteristics of rare subclonal mutations. Clonality estimates and covariates of
RMB in (top) the total high-coverage dataset and (bottom) a dataset resulting from downsampling to reduce variability in coverage across samples. Included from left to right, histograms
of CCF estimates across identified mutations, densities of RMB across samples, and correlation
analyses of RMB with average UMT coverage and tumor block age, with respective densities
indicated under the X-axis. These reveal that RMB increases as clonality decreases, as average
coverage increases, and as tumor block age increases. Down-sampling mitigated the residual
effect of coverage on RMB, while accentuating the residual effect of tumor block age.
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Figure 2.2: Late-stage primary tumors have increased rare subclonal genomic ITH. RMB in
early and later-stage primary tumors as determined at primary tumor diagnosis. RMBs result from
down-sampling UDS-UMI sequencing to reduce variability in coverage. P-values indicate
association significance for univariate (P, 1-sided Wilcoxon rank-sum test) and multivariate (P', 1sided logistic regression) tests, the latter of which includes tumor block age as a covariate.
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Figure 2.3: Rare subclonal genomic ITH predicts acquisition of alterations associated with
metastasis and/or treatment resistance. Association analysis of primary tumor RMB with (A)
the presence within primary tumors of specific alterations known to be associated with primary
tumorigenesis and (B) the acquisition within metastases of alterations and features previously
reported to be associated with breast cancer metastasis and/or treatment resistance. MT (mutant)
and WT (wild type) refer to patients whose tumor contain or lack the presence of genomic
features. Distinct CNAs are indicated by “loss” or “gain”. The bottom two panels result from
regression analysis of RMB. IHC analysis employed in (129) was used to determine the
proportion of nuclei positive for activated phospho-PKA. Values shown are RMB values resulting
from down-sampling used to reduce variability in UMT coverage. The number and color of
asterisks indicate levels of significance: univariate P ≤ 0.05 (red), P ≤ 0.15 (black); multivariate P'
≤ 0.05 (***); P' ≤ 0.10 (**), P' ≤ 0.15 (*)
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Figure 2.4: Clonality upper-bounds for “metastasis-specific” mutations that were not
detected by UDS-UMI in primary tumors. The maximum hypothetical clonality (minCCF95%) of
metastasis-specific mutations that were not detected by UDS-UMI and WES. Representative
mutations were chosen based on relevance to primary tumorigenesis and metastasis-enriched
SMGs and pathways. Solid and clear bars respectively indicate maximum hypothetical clonality
as determined by UDS-UMI and WES. Black arrowheads indicate minCCF95% values greater than
0.60. Same-color bars indicate that the same mutation remained undetected when multiple tumor
blocks from the same primary tumor were assayed. UDS-UMI had a median 95% power to detect
mutations that were present in greater than 2.7% of cells (dotted-line). WES had a median 95%
power to detect mutations that were present in greater than 54% of cells (dashed line).
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Figure 2.5: Clonal history of metastasis-specific mutations within primary tumors.
Estimated posterior distributions of CCF (violin-plots) for metastasis-specific mutations (blue) that
were detected by UDS-UMI in corresponding primary tumors (red). Distribution height indicates
the range of possible CCF values with the widest point indicating the most likely estimate for
CCF. Since the number of mutant alleles cannot be determined, CCF distributions are given for
both possible number of alleles (multiplicity factor) when applicable. P values indicate the
probability that the mutation within the metastasis was subclonal, with P > 0.95 indicating a likely
subclonal mutation. Dashed lines indicate a clonal mutation (CCF = 1).
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Table 2.1: Detection probabilities for metastasis-specific mutations. Based on the
background RMB and the number of metastasis-specific mutations assayed and detected,
probabilities that the given number of mutations were detected by chance were calculated for
each patient. Combined likelihood and permutation analyses indicate that it was unlikely that at
least one mutation was detected by chance in at least six patients, and that at least two mutations
were detected by chance in at least three patients.
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Chapter 3: Future Directions
3.1

Combinatorial inhibition of mTOR and CDK4/6 in breast cancer progression
Compared with paired primary tumors, the mTOR signaling pathway is preferentially copy

number altered (loss of STK11 and gain of PTK6, 1.2.4), preferentially mutated (1.2.5, 1.2.6), and
preferentially activated (1.2.7) within corresponding recurrent, metastatic tumors within patients.
Similarly, the CDK/RB pathway is preferentially copy number altered (loss of CDKN2A/B, 1.2.4;
increased frequencies of amplification and deletion of genes expected to lead to RB inactivation;
1.2.9); exhibited increases in mutations expected to lead to RB inactivation (1.2.9); and is hyper
inactivated in metastases compared with paired primary tumors (1.2.10).
Furthermore, there is a history of co-selection between mutations in these two pathways,
whereby patients whose primary tumors exhibited genomic alterations in one of these pathways
were more likely to give rise to metastases bearing genomic alterations in the other pathway. This
often leads to both pathways being mutated and dysregulated, as seen by the significant cooccurrence of at least one high-level CNA in each of these pathways (1.2.11). Furthermore, we
found that alterations that are expected to affect the CDK/RB pathway, including gain of CCNE1
and loss of TP53, were significantly associated with mTOR activity in metastases, a finding that is
consistent with accumulating evidence for extensive crosstalk between mTOR signaling and cell
cycle regulators (71).
As stated in the 1.3, mTOR pathway activation has been implicated as a mechanism of
escape from therapies that target ER and HER2 in pre-clinical models (60) and in breast cancer
patients (61). For example, treatment with the mTORC1 inhibitor everolimus improved
progression-free survival in patients with HR+HER2– metastatic breast cancer when administered
along with an aromatase inhibitor (62). Similarly, increased CDK4/6 activity in ER+ tumors is a
demonstrated mechanism of resistance to endocrine therapies (65), and that dual inhibition of
CDK4/6 and ER confers improved outcomes in patients with advanced breast cancer (66).
Consequently, while studies of the ability of CDK4/6 inhibitors (PALLAS, monarchE) or mTOR
inhibitors (SWOG/NRG/Alliance S1207) to prevent metastatic recurrence in early-stage breast
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cancer patients are underway, our finding that genomic alterations in these pathways co-occur in
patients suggest that combined pharmacological inhibition of mTOR and CDKs may more
effectively prevent, or treat, metastatic breast cancer than either agent alone. This prediction is
supported by observations that dual inhibition of these targets results in more pronounced
antitumor effects in breast cancer xenografts and cell lines in vitro (71).
Two small clinical trials found that combinatorial treatment (CDK4/6 and mTOR inhibitors)
had limited benefit on survival outcomes in patients (133)(134); however, in both cases, dual
inhibition was only administered after patients had previously progressed, and thus become
resistant, to either everolimus or palbociclib, respectively. Thus, it remains unclear to what extent
dual inhibition of the mTOR and CDK/RB pathways can treat advanced breast cancer in patients
unexposed to these inhibitors as well as prevent tumor recurrence and/or metastasis in patients
with early breast cancer.
To assess the extent to which dual inhibition prevents tumor recurrence and/or
metastasis, combinational inhibition of the mTOR (e.g. everolimus) and CDK/RB (e.g. palbociclib)
signaling pathways should be assessed in different mice from the doxycycline-inducible model of
breast cancer recurrence, MMTV-rtTA/TetO-NeuNT (MTB/TAN)(135). After primary tumors are
allowed to fully form (“dox-on”) and then regress (“dox-off”), the following should be measured in
the absence of therapy as well as after simultaneous and individual inhibition of the mTOR and
CDK/RB pathways: time to recurrence, time to metastasis, degree of local recurrence, number
and types of metastatic sites, and total metastatic tumor burden. The same experiments should
be implemented in the context of other commonly used targeted therapies. Based on the data
presented here, both treatments alone are expected to lead to a longer average time to
recurrence as well as mitigate metastatic spread, while simultaneous inhibition is expected to
lead to a synergistic increase in average time to recurrence as well as a further decrease in
metastatic spread and in the proportion of mice that recur. Demonstration of a synergistic effect of
mTOR and CDK/RB pathway inhibitors in the prevention or ablation of breast cancer recurrence
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and/or metastasis in mice would provide further support for simultaneous inhibition in treatmentnaïve patients within the adjuvant setting.
To assess the extent to which dual inhibition abrogates resistance to targeted therapies,
combinatorial treatment should be administered in a xenograft model of breast cancer recurrence
and metastasis. Specifically, the HR+ human cell-line, MCF7, should be orthotopically injected
into the mammary gland of mice. After these mice have formed palpable tumors in the mammary
gland, a drug course of fulvestrant with and without combinatorial inhibition of mTOR and CDK4/6
should be administered. Tumor volume, time to recurrence, and metastatic spread should then be
measured. To alternatively model the ability of these drugs to treat breast cancer in patients who
had previously progressed on targeted therapies (e.g. fulvestrant), the same experimental
schema should be implemented with the fulvestrant-resistant cell-line, MCF7/182R-6. I
hypothesize that dual inhibition of both the mTOR and CDK4/6 pathways will lead to a synergistic
increase in time to recurrence and decrease in metastatic spread, with an a larger effect being
more apparent when the 182R-6 cell-line is used.
The demonstration of a synergistic effect of dual inhibition of the mTOR and CDK/RB
pathways on survival outcomes in mouse and xenograft models of breast cancer recurrence
would further support dual inhibition in the clinic to both prevent treatment recurrence and
metastasis as well as treat patients who have progressed on otherwise effective targeted
therapies.
3.2

The effect of PAQR8 and PAQR7 stoichiometry on metastasis and treatmentresistance
The non-canonical, membrane-bound progesterone receptor (mPR), PAQR8, is

preferentially amplified – in a hyperfocal manner – in treatment refractory metastases compared
with paired primary tumors (1.2.4), suggesting that this poorly characterized gene may promote
processes underlying treatment resistance and/or metastasis. Further supporting its role in
treatment resistance is the mutual exclusivity pattern exhibited between gain of PAQR8 and
mutations in canonical hormone receptors, ESR1 and PGR, in patients exposed to anti-estrogen
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therapy, alluding to a redundant function between PAQR8 gain and mutations known to lead to
anti-estrogen therapy resistance (activating ESR1 mutations). Intriguingly, however, PAQR8 gain
occurred in similar frequencies in patients with and without anti-estrogen therapy and was one of
a few alterations that were shown to be significantly associated with increased mTOR activity
(pS6 IHC) in metastases (1.2.8), suggesting that PAQR8 gain may have an additional role in
promoting treatment-independent breast cancer progression and tumor survival.
Surprisingly, a closely related mPR, PAQR7, was found to be frequently lost in both primary
and recurrent, metastatic tumors in this dataset. Furthermore, these patterns (preferential gain of
PAQR8 in metastases, and frequent loss of PAQR7 in both primary and recurrent tumors) were
recapitulated in a large dataset of tumors from several doxycycline-inducible mouse models of
breast cancer recurrence (data and methods not shown). Because both PAQR7 and PAQR8
have been shown to form dimers in vitro (the extent to which these are homo- versus heterodimers has not been determined)(33); PAQR7 usually has much higher expression than PAQR8
across tissues (136); and PAQR7 has been shown to lead to inhibition of cAMP synthesis (136),
proliferation (137), and EMT (138); I hypothesize that the stoichiometry of PAQR7 to PAQR8
determines the ability of these mPRs to inhibit (high PAQR7, low PAQR8) or promote (low
PAQR7, high PAQR8) processes underlying treatment resistance, tumor cell survival, and/or
metastasis. A corollary to this is the hypothesis that PAQR8 is able to inhibit PAQR7 via
heterodimerization, thus resulting in increased cAMP synthesis, tumor cell survival, and
proliferation.
These effects could be assessed by transforming the doxycycline-inducible mouse breast
cancer cell line (“54074”), the human breast cancer cell-line (MCF7), as well as its corresponding
fulvestrant-resistant lineage (MCF7/182R-6) to combinatorially over-express PAQR8 via a pLenti6
vector (PAQR8-OE) and/or knock-out expression of PAQR7 via CRISPR targeting (PAQR7-KO).
To assess the role of PAQR7/PAQR8 stoichiometry in treatment resistance, cell viability should
be measured across increasingly larger doses of targeted therapies (e.g. fulvestrant or
trastuzumab) as well as a chemotherapeutic drug (e.g. paclitaxel). It is expected that these
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alterations would synergistically decrease sensitivity to targeted and non-targeted drugs, thus
leading to increased cell viability. The differentially ability of these alterations to decrease
sensitivity to targeted vs non-targeted drugs would inform their ability to promote targeted
treatment escape pathways versus overall tumor cell survival. These effects should then be
compared between MCF7 and MCF7/182R-6 cell-lines to be able to delineate the effects of these
alterations on tumor cell growth and survival versus treatment resistance.
The differentially ability of these cell-lines (PAQR7-WT/PAQR8-WT, PAQR7-WT/PAQR8OE, PAQR7-KO/PAQR8-WT, PAQR7-KO/PAQR8-OE) to metastasize should also be assessed
by injecting them orthotopically in the mammary gland, allow primary tumors to form (“dox-on”),
regress (“dox-off”) and then measure aspects of metastasis and treatment recurrence: time to
recurrence and metastasis, degree of local recurrence, number and types of metastatic sites, and
total metastatic tumor burden. These should also be measured in the context of targeted and
chemo- therapeutic drugs, as well as using tail vein injection instead of orthotopic injection to
better delineate to which underlying metastatic processes (tumor growth, dissemination,
intravasation, circulation, extravasation, and colonization) these alterations may promote.
3.3

LRP5 activation and PEAK1 inactivation in the promotion of metastatic
dissemination
The reconstructed evolutionary history of metastasis in one patient (2.2.8) revealed that the

metastasis likely arose from dissemination of an exceedingly rare primary tumor subclone (2% of
cells) that bore both a LRP5 activating missense mutation (CCF = 0.02) and a PEAK1 missense
mutation (CCF = 0.24) (described in 2.3). As stated in 1.3, LRP5 activates canonical WNT
signaling through its role as a co-receptor with LRP6 and Frizzled family members and is directly
inhibited by DKK1. Based on its structural similarity to the known LRP5 E171V activating
mutation, Bhat and colleagues (48) first predicted and then showed that the LRP5 A65V mutation
identified in our study confers enhanced resistance to its inhibition by DKK1, thereby activating
canonical WNT signaling. PEAK1, in turn, is involved in regulating focal adhesions and cell
migration and is one of seven SMGs that we found to be preferentially mutated in metastases
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(129). Due to an overall decrease in PEAK1 CN in metastases compared with primary tumors, as
well as the observation that five of the six PEAK1 mutations that we identified in metastases are
deleterious (2 nonsense, 3 missense that co-occur with CN loss), we previously hypothesized
that PEAK1 loss of function is selected for during metastatic progression. Together, these
observations raise the intriguing hypothesis that the ability of this rare primary tumor subclone to
seed a metastasis was influenced by the LRP5 A65V and PEAK1 K140Q mutations contained
within it. Furthermore, the fact that the corresponding metastasis in this case was synchronous
(discovered 9 days after primary tumor diagnosis), suggests that these mutations that lead to
WNT activation and focal adhesion dysregulation, respectively, specifically enhance metastatic
potential rather than treatment resistance.
The effects the LRP5 activation and PEAK1 inactivation have on metastasis could be
assessed by transforming the doxycycline-inducible mouse breast cancer cell line (“54074”) and
the human breast cancer cell-line (MCF7) to over-express the LRP5 A65V activating mutation via
a pLenti6 vector (LRP5-MT-OE) and/or knock-out expression of PEAK1 via CRISPR targeting
(PEAK1-KO). The differentially ability of these cell-lines (LRP5-WT/PEAK1-WT, LRP5WT/PEAK1-KO, LRP5-MT-OE/PEAK1-WT, LRP5-MT-OE/PEAK1-KO) to metastasize should be
assessed by injecting them orthotopically in the mammary gland, allow primary tumors to form
(“dox-on”), regress (“dox-off”) and then measure aspects of metastasis and treatment recurrence:
time to recurrence and metastasis, degree of local recurrence, number and types of metastatic
sites, and total metastatic tumor burden. These same measures should be assessed after tail
vein injection instead of orthotopic injection to better delineate to which underlying metastatic
processes (tumor growth, dissemination, intravasation, circulation, extravasation, and
colonization) these alterations may promote.
3.4

Nuclear PKA-specific effects on treatment resistance and/or metastasis
Together with the findings that cAMP signaling pathway was found to preferentially

mutated in metastases compared with paired primary tumors (1.2.5, 1.2.14) and that mutations in
the cAMP signaling pathway are more common within metastases whose patients were treated
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with either chemotherapy or radiation therapy suggests that dysregulation of this pathway may
drive processes of metastasis and/or treatment resistance. Supporting this hypothesis is the
finding that activated catalytic PKA (p-PKA T197) is preferentially nuclear in metastases
compared, a pattern that is relatively uncommon in paired primary tumors and has not been
reported in patient cancer tissue. As discussed in 1.3, other studies have reported that
phosphorylation of ER by PKA induces tamoxifen resistance in vitro (82) and that translocation of
pPKA to the nucleus mediates lung cancer metastasis in mice (83). Nevertheless, despite its
ubiquitous presence and broad cellular effects, cellular responses to increased levels of cAMP
are cell type and context specific (54, 84). It is therefore not surprising that conflicting evidence
exists regarding the role of PKA in tumorigenesis, metastasis, and treatment resistance (85, 86).
These apparent contradictions may be explained, at least in part, by the differential abundance of
PKA regulatory subunits (87), subcellular localization of cAMP resulting from selective
degradation by phosphodiesterases (PDEs) (88), and/or subcellular localization of activated PKA
through binding to compartment-specific A-kinase anchoring proteins (89). Since both activators
(e.g., forskolin) (90) and degraders (e.g., PDE4) (91) of cAMP are being evaluated in the clinic,
the complex effects of cAMP/PKA pathway activation during cancer progression would benefit
from further investigation.
To assess the ability of activated nuclear PKA to promote processes of treatment
resistance and/or metastasis, a system should be first created that allows ablation and
inducement of constitutively active PKA specifically to nuclei. For example, since AKAP95 and
PDE4 have been shown to cooperate to produce a nuclear microdomain that tightly controls
nuclear PKA and cAMP levels (139), both should be combinatorially over-expressed in breast
cancer cell lines (both mouse in human) to determine their ability to promote nuclear specific
localization and effects of activated PKA. Alternatively, nuclear vs cytoplasmic PKA could be
induced via ligation of a nuclear localization signal (NLS) and nuclear export signal (NES) peptide
chains to PKA, respectively.
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PRKACA encodes the predominant catalytic sub-unit of PKA (C ). The Leu206Arg
(c.617A>C) mutation within PRKACA, which recurrently occurs in adrenocortical tumors, has
been shown to lead to constitutive activation of PKA by abolishing the interaction between C
and inhibitory, regulatory sub-units (RIα, RIβ, RIIα, and RIIβ)(140). To maintain a constitutively
active state of PKA in transformed cells, the Leu206Arg (c.617A>C) should be knocked-in using
CRISPR, followed by a mutational analysis in transformed cells to ensure that transformation
resulted in homogenous population of cells in which both alleles express the activating mutation.
Once one (or more) experimental systems have been shown to lead to ablation or
induction of the localization of activated PKA to nuclei, we can assess the ability of these
perturbations to promote processes of treatment resistance and metastases using similar
frameworks as described in 3.1-3.3. Nuclear localization of activated PKA would then be
expected to lead to increased metastatic tumor potential as well as desensitivity to targeted and
non-targeted therapies in vitro and in vivo.
3.5

Further refinements and broader impact
In addition to experiments described above, the genomic datasets and analyses described

herein could be expanded by the following analyses: the construction of a predictive model that
takes into account the multi-dimensional aspect of these integrated genomic sequencing datasets
via multiple data-specific coefficients for regularization and/or a decision tree framework to
identify complex relationships between features that may promote treatment resistance and/or
metastasis; leveraging the multiple region assay aspect of the UDS-UMI dataset for both
validation as well as to elucidate the amount of rare subclonal heterogeneity that is shared across
separate regions of a primary tumor; as well as the evaluation of a FFPE-specific artifact filtering
criteria. Furthermore, the same experimental framework may be able to identify other genomic
features that preferentially occur in metastases, including differential: gene expression;
chromosome regulatory structure micro-domains; alternative-splicing; gene fusions; noncoding
RNA; translocations; methylation; and DNA translocation events.
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While some potential experiments have been highlighted, results presented here have also
opened many other research avenues; for example, preferential mutation of specific genes:
MYLK, PEAK1, XIRP2, PALB2, EVC2, and SLC2A4RG; and pathway gene sets: HKMTs, focal
adhesion, prolactin signaling, VEGF signaling, platelet activation, Rap1 signaling, and relaxin
signaling. Furthermore, since rare subclonal mutation burden within primary tumors has been
shown to be associated with more advanced primary tumors and to be predictive of the
acquisition of mutations and alterations in implicated metastasis-enriched features, the extent to
which RMB drives processes of metastasis and aggression rather than being a mere
consequence of the same processes should be investigated.
Since the great majority of breast cancer deaths result from treatment-refractory recurrent,
metastatic breast cancer, I hope that the experiments outlined herein will be able to validate new
therapeutic approaches as well as new targets in the prevention and treatment of this more
aggressive form of the disease. With a new treatment strategy paradigm, the majority of patients
suffering from breast cancer may be able to survive more than five years after primary tumor
resection.
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APPENDIX
Chapter 1 Supplemental Tables can be found with the corresponding publication (129) in the
Journal of Clinical Investigation (https://www.jci.org/articles/view/129941#sd)
Supplemental Table 1: Sheet 1: Clinical annotation for each genomically assayed
patient, including information on metastatic tumor site, receptor subtype, summary
treatment information, and whether the paired primary tumor from the same patient was
genomically assayed. Sheet 2: Clinical annotation provided by TCGA is given for the
1,044 primary tumors used as a reference set throughout the study.
Supplemental Table 2: Sheet 1: MutSigCV2 output used to identify the 15 SMGs
identified in the total metastatic tumor cohort. Sheet 2: Mutations in clinically relevant
receptors (ESR1, ERBB2, PGR). Sheet 3: Mutations in SMGs determined by MutSigCV2.
Sheet 4: Comparison of SMG frequencies between metastatic tumors in our cohort and
TCGA-BRCA primary tumors using low and high-confidence variant calling thresholds.
Variants within the TCGA-BRCA data set were re-called using the same variant calling
pipeline employed in this study.
Supplemental Table 3: Sheets 1-4: GISTIC2 results for genomically assayed primary
and metastatic tumors. Sheet 5: Analysis of differences in normalized copy number and
CNA frequencies in SARs identified by GISTIC2 between paired primary and metastatic
tumors and between total tumor cohorts.
Supplemental Table 4: Sheets 1-3: SMPs identified in paired primary tumors, paired
metastases, and all metastases, respectively. Sheet 4: Mutation frequencies and
enrichment P-values for each pathway. Sheet 5: Information on mutations detected in
metastasis-enriched SMPs.
Supplemental Table 5: Sheets 1 and 2: SMPs identified within the TCGA-BRCA primary
tumor cohort and the Lefebvre et al. metastatic tumor cohort, respectively. Sheet 3:
Mutation frequencies and enrichment P-values are given for each pathway.
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Supplemental Table 6: The number of WT and mutant samples for each p-S6 biomarker
within the paired primary-metastatic tumor cohort assayed by p-S6 IHC, as well as
resulting P-values when comparing p-S6 intensities.
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